Page last updated: 2024-08-17

uridine monophosphate and sofosbuvir

uridine monophosphate has been researched along with sofosbuvir in 485 studies

Research

Studies (485)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	463 (95.46)	24.3611
2020's	22 (4.54)	2.80

Authors

Authors	Studies
Hartmann, MD; Heim, C; Hernandez Alvarez, B; Maiwald, S	1
Bansal, S; Bao, D; Bao, H; Chang, W; Espiritu, C; Furman, PA; Lam, AM; Murakami, E; Niu, C; Otto, MJ; Sofia, MJ; Steuer, HM; Tolstykh, T	1
Bansal, S; Bao, D; Chang, W; Du, J; Espiritu, C; Furman, PA; Keilman, M; Lam, AM; Nagarathnam, D; Niu, C; Otto, MJ; Rachakonda, S; Reddy, PG; Ross, BS; Sofia, MJ; Steuer, HM; Wang, P; Zhang, HR	1
Lawitz, EJ; Membreno, FE	1
Rachakonda, S; Reddy, PG; Ross, BS; Sofia, MJ; Zhang, HR	1
Bao, D; Chang, W; Chun, BK; Du, J; Espiritu, CL; Furman, PA; Jiang, Y; Keilman, M; Ross, BS; Sofia, MJ; Steuer, HM; Zhang, HR	1
Chee, GM; Poordad, F	1
Ferenci, P	2
Mangia, A; Mottola, L	1
Bansal, S; Espiritu, C; Furman, PA; Keilman, M; Lam, AM; Lan, S; Micolochick Steuer, HM; Niu, C; Otto, MJ; Zennou, V; Zhu, Y	1
Barreiro, P; Fernández-Montero, JV; Poveda, E; Soriano, V; Vispo, E	1
Dieterich, DT; Martel-Laferrière, V	2
Pockros, PJ	1
Albanis, E; Berrey, MM; Cornpropst, MT; Dejesus, E; Hebner, CM; Jiang, D; Kowdley, KV; Lalezari, J; Lawitz, E; Mader, M; McHutchison, JG; Nelson, DR; Rodriguez-Torres, M; Symonds, WT	1
Berrey, MM; Ding, X; Gane, EJ; Hindes, RG; Hyland, RH; Stedman, CA; Svarovskaia, E; Symonds, WT	1
Desoky, OS; Elfiky, AA; Elshemey, WM; Gawad, WA	1
Herbst, DA; Reddy, KR	1
Cornberg, M; Manns, MP	1
Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT	1
Burney, T; Dusheiko, G	1
Afdhal, N; Albanis, E; An, D; Anderson, JK; Bernstein, DE; Berrey, MM; Crespo, I; Davis, MN; DeMicco, M; Dvory-Sobol, H; Gordon, SC; Hassanein, T; Hindes, RG; Hyland, RH; Jacobson, IM; Kowdley, KV; Lawitz, E; Nelson, DR; Symonds, WT; Vierling, JM	1
Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA; Symonds, WT	1
Drenth, JP	2
Al-Assi, MT; An, D; Bennett, M; Brainard, D; Everson, G; Feld, J; Gordon, SC; Jacobson, IM; Kowdley, KV; Lawitz, E; Lin, M; McHutchison, JG; McNally, J; Nelson, DR; Patel, K; Pianko, S; Rodriguez-Torres, M; Schiff, E; Shiffman, ML; Subramanian, GM; Sulkowski, MS; Symonds, WT; Yoshida, EM	1
Arterburn, S; Brainard, D; Davis, MN; Gane, EJ; Gordon, SC; Hassanein, T; Hyland, RH; Jacobson, IM; Jiang, D; Kayali, Z; Kowdley, KV; Lawitz, E; Mangia, A; McHutchison, JG; McNally, J; Nyberg, L; Reddy, KR; Rodriguez-Torres, M; Schultz, M; Sheikh, AM; Subramanian, GM; Symonds, WT; Wyles, D; Younossi, Z	1
Mole, B	1
Dalzell, MD	1
Tse, MT	1
Wang, FS; Wang, LF; Zeng, QL; Zhang, JY; Zhang, Z	1
Johnson, MS	1
Borgia, F; Borgia, G; Buonomo, AR; Castaldo, G; Gentile, I	1
Bukh, J; Gottwein, JM; Jensen, SB; Li, YP; Pedersen, J; Ramirez, S	1
Barrett, L; Bon, D; Chavez, J; Dewar, R; Fauci, AS; Fishbein, D; Gu, W; Herrmann, E; Heytens, L; Highbarger, H; Kleiner, D; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Polis, MA; Proschan, M; Shivakumar, B; Silk, R; Sneller, M; Subramanian, M; Symonds, WT; Talwani, R; Teferi, G; Wood, BJ; Wroblewski, S; Zhang, X	1
Berrey, MM; Cornpropst, MT; Denning, J; Gao, B; Lawitz, EJ; Mathias, A; Mo, H; Rodriguez-Torres, M; Symonds, WT	1
Flisiak, R; Jaroszewicz, J; Parfieniuk-Kowerda, A	1
Chen, WC; Lee, JC; Lin, CK; Sun, HY; Tseng, CK; Wang, SW; Wu, YH; Young, KC	1
Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM	1
Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT	1
Doyle, JS; Hellard, ME	1
Rodríguez-Torres, M	1
Berg, T; Forns, X; Mariño, Z; van Bömmel, F	1
Ding, X; Gane, EJ; Hyland, RH; McHutchison, JG; Pang, PS; Stedman, CA; Subramanian, GM; Svarovskaia, E; Symonds, WT	1
Asselah, T	1
Gane, E; Gerber, L; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM	1
Gane, E; Henry, L; Hunt, S; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM	1
Cohen, J	2
Bon, D; Herrmann, E; Kottilil, S; Masur, H; Meissner, EG; O'Brien, TR; Osinusi, A; Prokunina-Olsson, L; Tang, W	1
Corouge, M; Pol, S; Vallet-Pichard, A	1
Boccaccio, V; Bruno, S	1
Asselah, T; Marcellin, P	1
Asselah, T; Halfon, P; Marcellin, P; Schinazi, R	1
Benhamou, Y; Shiffman, ML	1
Traynor, K	1
Harrison, C	1
Koff, RS	1
Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B	1
Sheridan, C	1
Eley, T; Everson, GT; Gao, M; Gardiner, DF; Grasela, DM; Hassanein, T; Hernandez, D; Hindes, R; Hinestrosa, F; Huang, SP; Jacobson, I; Lawitz, E; Lok, AS; McPhee, F; Nelson, DR; Pasquinelli, C; Reddy, KR; Rodriguez-Torres, M; Schwartz, H; Sherman, D; Sulkowski, MS; Symonds, W; Thuluvath, PJ; Wind-Rotolo, M	1
Keating, GM; Vaidya, A	1
Denning, J; Guedj, J; Lawitz, E; Pang, PS; Perelson, AS; Rodriguez-Torres, M; Symonds, W	1
Evon, DM	1
Fralick, M	1
Alcaro, S; Artese, A; Ceccherini-Silberstein, F; Cento, V; Costa, G; Di Maio, VC; Mirabelli, C; Perno, CF	1
Dugum, M; O'Shea, R	1
Asch, DA; Mehta, SJ	1
Shiffman, ML	1
Chung, RT; deLemos, AS	1
Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N	1
Berger, R; Conrad, JC; MacMillan, DW; Peifer, M; Shurtleff, VW	1
Hagan, LM; Schinazi, RF; Sulkowski, MS	1
Bruno, R; Cabibbo, G; Cammà, C; Craxì, A; Enea, M; Gasbarrini, A; Macaluso, FS; Petta, S; Plaia, A	1
Gane, E; Hunt, SL; Jacobson, IM; Lawitz, E; Nader, F; Nelson, D; Stepanova, M; Younossi, ZM	1
Dusheiko, G; Esteban, R; Hezode, C; Hunt, SL; Nader, F; Reesink, HW; Stepanova, M; Weiland, O; Younossi, ZM; Zeuzem, S	1
An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT	1
Watts, G	1
Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M	1
Hoofnagle, JH; Sherker, AH	1
Afdhal, N; Arora, S; Di Bisceglie, AM; Dvory-Sobol, H; Ghalib, R; Gitlin, N; Gordon, SC; Herring, R; Kwo, P; Lalezari, J; Lawitz, E; McHutchison, JG; Muir, AJ; Nahass, R; Nelson, DR; Pang, PS; Pockros, PJ; Reddy, KR; Schiff, E; Subramanian, GM; Sulkowski, M; Symonds, WT; Yang, JC; Younes, ZH; Zhu, Y	1
Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S	1
Muir, AJ	1
Callaway, E	1
Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A	1
Feld, JJ	1
Grewal, P; Kim, B; Thung, SN; Trivedi, A	1
Sofia, MJ	1
Brainard, DM; Dusheiko, GM; Esteban, R; Ferenci, P; Flisiak, R; Hézode, C; Hyland, RH; Illeperuma, A; Mangia, A; McHutchison, JG; Reesink, HW; Salupere, R; Subramanian, GM; Svarovskaia, E; Symonds, WT; Weiland, O; Zeuzem, S	1
Redberg, RF; Steinbrook, R	1
Ollendorf, DA; Pearson, SD; Tice, JA	1
Linas, BP; Pho, MT	1
Hayden, EC	1
Borgia, G; Buonomo, AR; Coppola, N; Gentile, I; Zappulo, E	1
Chan, J	1
Alexander, P; James, A; Long, AG; Shiffman, ML	1
Chiba, K; Fu, Z; Furihata, T; Kobayashi, K; Matsumoto, S; Sun, Y; Tsubota, A	1
Adler, H; Lambert, JS	1
Rice, CM; Saeed, M	1
Fadda, V; Gatto, R; Maratea, D; Messori, A; Trippoli, S	1
Hussar, DA	1
Senior, M	1
Slomski, A	1
Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E	1
Henry, L; Lam, B; Younossi, Z	1
German, P; Mathias, A; Moorehead, L; Pang, P; Vimal, M	1
Einecke, D	2
Fadda, V; Maratea, D; Messori, A; Trippoli, S	1
Keating, GM	1
Burki, T	1
Bon, D; Fauci, AS; Herrmann, E; Hewitt, S; Kottilil, S; Masur, H; McHutchison, J; Meissner, EG; Osinusi, A; Polis, M; Porcella, S; Prokunina-Olsson, L; Sturdevant, D; Suffredini, AF; Virtaneva, K; Wang, H; Wu, D	1
Rizza, SA; Talwani, R; Temesgen, Z	1
Andreoli, A; Angelico, M; D'Offizi, G; Durand, C; Ferenci, P; Knop, V; Lenci, I; Lionetti, R; Montalbano, M; Pellicelli, AM; Telese, A; Zeuzem, S	1
Chung, RT; Feeney, ER	1
Rolland, S; Vachon, ML	1
Cooke, G; Hill, A	1
Carroll, J	2
Demko, P; Dickson, V	1
Goozner, M	2
Chang, H; Han, Q; Li, N; Liu, X; Liu, Z; Lv, Y; Wang, Y; Zhang, G; Zhu, Q	1
Brennan, T; Shrank, W	1
Bourhis, F; Cure, S; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM	1
Andreone, P; Bernardi, M; Foschi, FG; Loggi, E; Margotti, M; Morelli, MC; Pinna, AD; Vukotic, R	1
Ahmed, A; Gordon, SC; Park, H; Saab, S; Sulkowski, M; Younossi, Z	1
Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P	1
Beumont, M; Callewaert, K; Corregidor, A; DeJesus, E; Fevery, B; Ghalib, R; Gitlin, N; Jacobson, IM; Lambrecht, T; Lawitz, E; Lim, JK; Lindsay, KL; Ouwerkerk-Mahadevan, S; Pearlman, B; Picchio, G; Pockros, PJ; Rabinovitz, M; Rodriguez-Torres, M; Scott, JD; Sulkowski, MS; Symonds, WT; Younossi, ZM	1
Brainard, D; Chodavarapu, K; Crespo Garcia, J; De Knegt, R; Doehle, B; Drenth, JP; Gontcharova, V; Hedskog, C; McHutchison, JG; Miller, MD; Mo, H; Stamm, LM; Svarovskaia, E	1
Donaldson, EF; Harrington, PR; Naeger, LK; O'Rear, JJ	1
Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C	1
Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F	1
Beavers, JW; Klibanov, OM; Summers, BB	1
Price, JC; Terrault, NA	1
Aghemo, A; De Francesco, R	1
Beigelman, L; Deval, J; Symons, JA	1
Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O	1
Abd-Rabou, AA; Belousova, V; Mousa, SA	1
Kottilil, S; Lee, YJ; Masur, H; McHutchison, J; Meissner, EG; Naggie, S; Osinusi, A; Patel, K; Qin, J; Remaley, AT; Sampson, M; Sims, Z; Sturdevant, D; Subramanian, M	1
Wapner, J	1
Kuehn, BM	1
Campos-Varela, I; Peters, MG; Terrault, NA	1
Cook, C; Phelan, M	1
Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA	1
Bekele, N; Brainard, D; Chiu, S; Dvory-Sobol, H; Gane, E; Gontcharova, V; Han, B; Hebner, C; Jacobson, IM; Ku, K; Lawitz, E; Martin, R; McHutchison, JG; Miller, MD; Mo, H; Nelson, DR; Ouyang, W; Parkin, N; Svarovskaia, ES; Symonds, WT; Wyles, DL; Xu, S	1
Foster, GR	2
Buclin, T; Chtioui, H; Moradpour, D	1
Chan, E; Gandhi, M; Lim, SG	1
De Silva, S; Foster, GR	1
Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA	1
Blázquez, A; Gimeno-Ballester, V; Mar, J; San Miguel, R	1
Dillon, JF; Miller, MH; Paterson, JC	1
Beavers, KL; Brainard, DM; Chuang, SM; Ding, X; Gane, EJ; Herring, RW; Jacobson, IM; Lawitz, E; Ma, J; McHutchison, JG; McNally, J; Ratziu, V; Reddy, KR; Stamm, LM; Sulkowski, MS; Symonds, WT; Wang, J; Yoshida, EM	1
An, D; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Poordad, F; Symonds, WT	1
Beaumont, JL; Beckerich, F; Cordonnier, C; Gautier, E; Hézode, C; Maury, S; Robin, C	1
Goldhaber-Fiebert, JD; Holodniy, M; Liu, S; Watcha, D	1
Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA	1
Alqahtani, SA; Dhingra, A; Kapoor, S	1
Rojas, Á; Romero-Gómez, M	1
Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X	1
Baak, LC; Bakker, CM; Berden, FA; Beuers, U; Boucher, CA; Brouwer, JT; Burger, DM; de Knegt, RJ; Drenth, JP; Hoepelman, AI; Honkoop, P; Kerbert-Dreteler, MJ; Kievit, W; Koek, GH; Tan, AC; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, CM; van Soest, H; Vrolijk, JM	1
Firpi, RJ; Hilgenfeldt, E	1
Cornberg, M; Höner zu Siederdissen, C	1
Charlton, MR; Gallegos-Orozco, JF	1
Amin, R; Koroglu, A; McGuey, L; McNutt, LA; Miller, C; Nasiri, M; Patel, N; Roman, M	1
Jacobson, IM; Kumar, S	1
Birnkrant, D; Connelly, S; Donaldson, E; Florian, J; Mishra, P; Murray, J; Naeger, LK; O'Rear, J; Price, D; Qi, K; Zeng, W	1
Ghany, MG; Liang, TJ	1
Aghemo, A; Donato, MF	1
Adhoute, X; Ansaldi, C; Bourlière, M; Castellani, P; Oules, V	1
Henry, L; Younossi, Z	1
Alberti, A; Piovesan, S	1
Mangia, A; Piazzolla, V	1
Baiguera, C; Panzeri, C; Puoti, M; Rossotti, R	1
Hablas, A; Hutton, DW; Kim, DD; Raouf, AA; Salama, M; Seifeldin, IA; Soliman, AS	1
Schwartz, M	1
Chan, J; Mohammad, RA; Smith, MA	1
Jensen, DM; Welch, NM	1
Serfaty, L	1
Ansaldi, C; Benali, S; Bourlière, M; Le Folgoc, G; Lecomte, L; Riso, A	1
Abdel-Razek, W; Waked, I	1
Nelson, DR; Peter, J	1
Baumert, TF; Brainard, D; Brandt-Sarif, T; Castells, L; Chang, P; Charlton, M; Coilly, A; Denning, J; Fontana, RJ; Forns, X; Habersetzer, F; Kivett, V; Londoño, MC; McHutchison, JG; Prieto, M; Symonds, WT	1
Ehleben, C; Pearlman, BL; Perrys, M	1
Terpening, CM	1
Hunt, DP	1
Hunt, SL; Naggie, S; Orkin, C; Puoti, M; Stepanova, M; Sulkowski, M; Younossi, ZM	1
Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ	1
Haley, SJ; Kreek, MJ	1
Bennett, M; Bernstein, D; Cooper, JN; Freilich, BF; Ghalib, R; Gitlin, N; Harlan, W; Hawkins, T; Hennicken, D; Hughes, EA; Kowdley, KV; Lalezari, JP; Lawitz, E; McPhee, F; Nelson, DR; Oguchi, G; Ortiz-Lasanta, G; Pockros, PJ; Rabinovitz, M; Rana, K; Ravendhran, N; Sheikh, AM; Thuluvath, PJ; Varunok, P; Younes, ZH	1
Ahmed, A; Dieterich, D; Gordon, SC; Park, H; Saab, S; Younossi, ZM	2
Brainard, D; Gaggar, A; Gonzalez, M; Kirby, B; McHutchison, JG; Rodriguez-Orengo, J; Rodriguez-Torres, M; Shen, G; Svarovskaia, E; Symonds, WT	1
Denk, G; Eberle, J; Guba, M; Kaspar, M; Kolligs, F; Pichler, M; Seybold, U; Spannagl, M; Stemberger, M	1
Afdhal, N; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S	1
Aghemo, A; Colombo, M; D'Ambrosio, R	1
Brainard, D; Gaggar, A; Iser, DM; Massetto, B; McHutchison, JG; Molina, JM; Nelson, M; Ni, L; Orkin, C; Puoti, M; Rockstroh, JK; Stephan, C; Subramanian, GM; Svarovskaia, E; Zamora, FX	1
Kim, AY; Naggie, S	1
Kumari, R; Nguyen, MH	1
Appleby, TC; Barauskas, O; Cho, A; Edwards, TE; Feng, J; Fox, D; McGrath, ME; Murakami, E; Perry, JK; Ray, AS; Sofia, MJ; Swaminathan, S; Wetmore, DR	1
Beckerman, R; Jiang, Y; Smith, NJ; Stepanova, M; Younossi, ZM	1
Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT	1
Floreani, A	1
Füessl, HS	1
Jäger-Becker, D	1
Caldwell, SH; Cornella, SL; Kelly, V; Shah, NL; Stine, JG	1
Abergel, A; Alric, L; Bourlière, M; Bronowicki, JP; de Ledinghen, V; Doehle, B; Grangé, JD; Guyader, D; Habersetzer, F; Hézode, C; Hyland, RH; Jiang, D; Larrey, DG; Leroy, V; Loustaud-Ratti, V; Marcellin, P; Mathurin, P; McHutchison, JG; Metivier, S; Pang, PS; Pol, S; Ratziu, V; Serfaty, L; Subramanian, GM; Symonds, WT; Tran, A; Zoulim, F	1
Chhatwal, J; Dunn, MA; Kanwal, F; Roberts, MS	1
Andersson, K; Avorn, J; Brennan, T; Choudhry, NK; Krumme, AA; Matlin, OS; Najafzadeh, M; Shrank, WH	1
Liffmann, DK; Rein, DB; Smith, BD; Ward, JW; Wittenborn, JS	1
Hayward, P	1
Sekkides, O	1
Assoumou, SA; Barter, DM; Freedberg, KA; Horsburgh, CR; Kim, AY; Leff, JA; Linas, BP; Morgan, JR; Pho, MT; Salomon, JA; Schackman, BR; Weinstein, MC	1
Manns, MP; Wedemeyer, H; Zeuzem, S	1
Flamm, S; Lawitz, E; McHutchison, JG; Morelli, G; Pang, PS; Pockros, P; Svarovskaia, E; Wyles, D; Yang, JC; Younes, Z; Zhu, Y	1
Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S	1
Bennett, M; Brainard, D; Doehle, B; Gane, EJ; Hassanein, T; Jacobson, IM; Kanwar, B; Liu, L; McHutchison, JG; Mo, H; Nahass, RG; Pol, S; Subramanian, GM; Sulkowski, MS; Symonds, WT	1
Brault, P; Klotz, C; Mallet, V; Pol, S; Sultanik, P	1
Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O	1
Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S	1
Beebe, A; Gicquelais, RE; Haselow, DT; Patil, N; Quattlebaum, T; Smith, NH; Zohoori, N	1
Afdhal, N; Arterburn, S; Brandt-Sarif, T; Brown, K; Brown, RS; Charlton, M; Denning, J; Dvory-Sobol, H; Everson, GT; Flamm, SL; Fontana, RJ; Fried, MW; Gilroy, R; Korenblat, KM; Kumar, P; Kuo, A; Kwo, P; Landis, C; McHutchison, JG; Muir, AJ; O'Leary, JG; Pang, PS; Pungpapong, S; Reddy, KR; Schiff, E; Sulkowski, MS; Teperman, L; Terrault, NA; Vargas, HE; Watt, KD	1
Warpakowski, A	2
Feld, JJ; Shah, H; Sheehan, K; Sockalingam, S	1
Bagcchi, S	1
Halász, T; Horváth, G; Hunyady, B; Makara, M	1
Fazel, Y; Golabi, P; Lam, B; Younossi, Z	1
Kmietowicz, Z	2
Barua, S; Dore, GJ; Grebely, J; Greenwald, R; Swan, T; Taylor, LE	1
Canary, LA; Holmberg, SD; Klevens, RM	1
McCarthy, M	2
Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F	1
Berg, T; Manns, MP; Zeuzem, S	1
Ackerman, P; Dieterich, D; Dretler, R; Fishbein, D; Gathe, JC; Henn, S; Hinestrosa, F; Hughes, E; Huynh, C; Liu, Z; Luetkemeyer, A; McDonald, C; McPhee, F; Mills, A; Morgan, TR; Noviello, S; Overton, ET; Ramgopal, M; Rashbaum, B; Ray, G; Ruane, PJ; Scarsella, A; Sherman, KE; Sulkowski, MS; Wyles, DL; Yin, PD; Yozviak, J	1
Baden, RP; Bräu, N; Colson, AE; Cooper, C; Dieterich, D; Dvory-Sobol, H; Gane, E; German, P; Jayaweera, D; Luetkemeyer, A; Marks, K; McHutchison, JG; Morales-Ramirez, JO; Naggie, S; Ni, L; Pang, PS; Ruane, P; Saag, M; Santana-Bagur, J; Sax, PE; Stamm, LM; Stedman, CA; Sulkowski, M; Tebas, P; Towner, WJ; Wong, DK; Workowski, K; Yang, JC	1
Alexander, PC; James, AM; Long, AG; Shiffman, ML	1
Bastian, ND; Griffin, PM; Zhang, S	1
Cornberg, J; Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Kirschner, J; Manns, MP; Mix, C; Mix, H; Port, K; Solbach, P; Sollik, L; Wedemeyer, H; Worzala, D	1
Klibanov, OM; Lomberk, M	1
Buti, M; Esteban, R; Riveiro-Barciela, M	1
Bertuccio, C; Chau, H; Ciarleglio, M; Cohen, E; Deng, Y; Do, A; Drozd, K; Eggers, C; Liapakis, A; Lim, JK; Mittal, Y; Sapir, D; Wright, J	1
Fischer, MA; Liao, JM	1
Brainard, DM; Chung, RT; Doehle, B; Gustafson, J; Kim, AY; Lauer, GM; Liu, L; McHutchison, JG; Mo, H; Pang, PS; Simon, TG; Stamm, LM	1
Gibson, W; Klibanov, OM; Mullins, C	1
Ryder, SD; Thiagarajan, P	1
Bagate, F; Boueyre, E; Corouge, M; Duboc, D; Fontaine, H; Lazarus, A; Mallet, V; Pecriaux, C; Pol, S; Sogni, P; Sultanik, P; Vallet-Pichard, A	1
Afdhal, N; Gitlin, N; Howell, C; Jeffers, LJ; Kowdley, K; McHutchison, JG; Muir, AJ; Pang, PS; Poulos, J; Ravendhran, N; Reddy, KR; Shiffman, ML; Sulkowski, MS; Wilder, JM; Workowski, K; Yang, JC; Zhu, Y	1
Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K	1
Burger, J; Dranitsaris, G; Fraser, I; Lubbe, M; Sonderup, M; Stander, T	1
Dyson, JK; McPherson, S	1
Dominguez-Dominguez, L; Jarrin-Estupiñan, ME; Kessler-Saiz, P; Marchan-Lopez, A	1
Jhaveri, KD; Schwartz, D; Thakkar, J; Wanchoo, R	1
Hoofnagle, JH	1
Rivero, A; Rivero-Juárez, A	1
Rieger, KE; Scott, GD	1
Afdhal, N; Charlton, M; Denning, J; Everson, GT; Flamm, SL; Hyland, R; Lin, M; McHutchison, JG; Pang, PS; Reddy, KR; Welzel, TM; Zeuzem, S	1
Dickinson, K; Harrison, P; Ryder, S; Simpson, EL; Stevens, JW; Tappenden, P; Thokala, P	1
Agarwal, K; Angus, P; Arterburn, S; Brainard, D; Buti, M; Calleja, JL; Colombo, M; Denning, J; Dufour, JF; Dvory-Sobol, H; Forns, X; Gane, EJ; Manns, M; McCaughan, G; McHutchison, JG; Müllhaupt, B; Mutimer, D; Pang, PS; Peck-Radosavljevic, M; Prieto, M; Rizzetto, M; Samuel, D; van Hoek, B; Van Vlierberghe, H; Yoshida, EM	1
Chandrasekar, PH; Surapaneni, M; Wahba, MR	1
Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA	1
Brainard, D; German, P; Kearney, BP; Mathias, A	1
Brainard, DM; De-Oertel, S; Doehle, B; Dvory-Sobol, H; Izumi, N; Knox, S; Miller, MD; Mizokami, M; Mo, H; Nishiguchi, S; Omata, M; Sakamoto, N; Svarovskaia, ES; Takehara, T	1
Ahn, SH; Byun, KS; Gao, B; Garrison, KL; Han, KH; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mo, H; Paik, SW; Pang, PS; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK	1
Beyer, P; de Joncheere, K; Hill, S; Iyengar, S; Tay-Teo, K; Vogler, S; Wiktor, S	1
Bischoff, M	1
Ahmed, A; Dieterich, D; Ferguson, JR; Gordon, SC; Park, H; Saab, S; Younossi, ZM	1
Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI	1
Flemming, JA; Lowe, CE	1
Afdhal, NH; Brainard, DM; Chuang, SM; Ding, X; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Ma, J; McHutchison, JG; Miller, MD; Mo, H; Pang, PS; Sarrazin, C; Svarovskaia, ES	1
Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A	1
Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A	1
Al-Tarawneh, M; Bader, G; Cook, E; Pourmorteza, M; Shams, W; Tawadros, F; Young, M	1
Leshno, M; Malnick, SD; Maor, Y; Melzer, E	1
Blumberg, EA; Doyle, AM; Lee, DH; Sawinski, D	1
Afdhal, NH; Buti, M; Curry, MP; Dufour, JF; Firdoos, S; Flamm, S; Hughes, MS; Tapper, EB	1
Appolo, B; Bloom, R; Patel, N; Sawinski, D	1
Ahn, J; Branch, A; Gripshover, J; Hassan, MA; Kwok, RM; Lee Sang, M; Patel, N; Potosky, DR; Robertazzi, S; Rodigas, C; Satoskar, R; Schiano, TD; Smith, CI; Te, HS; Tierney, A; Wiegel, J	1
Akushevich, L; Ben Ari, Z; Di Bisceglie, AM; Frazier, LM; Fried, MW; Kuo, A; Lim, JK; Lok, AS; Nelson, DR; Pockros, PJ; Shiffman, ML; Sulkowski, MS; Terrault, NA; Vainorius, M; Zeuzem, S	1
Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X	1
Furusyo, N; Hayashi, J; Hotta, T; Murata, M; Ogawa, E; Shimizu, M; Toyoda, K; Uchiumi, T	1
De Weggheleire, A; Dorlo, TP; Francque, S; Lynen, L; Meessen, B; Newton, PN; Pouget, C; Ravinetto, R; Sokkab, A; Tabernero, P	1
Beckman, AL; Bilinski, A; Boyko, R; Bruce, RD; Camp, GM; Gonsalves, GS; Lim, JK; Wall, AT; Wang, EA	1
Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL	1
Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM	1
Song, YK; Tong, Y; Tyring, S	1
Cuenca-Lopez, F; Rivero, A; Rivero-Juárez, A	1
Christiansen, H; Graf Einsiedel, H; Wiegand, J	1
Heppt, F; Sticherling, M	1
Afdhal, NH; Brainard, DM; Doehle, BP; Dvory-Sobol, H; Gane, EJ; Kowdley, KV; Lawitz, E; Martin, R; Miller, MD; Mo, H; Svarovskaia, ES; Wyles, D	1
Kahn, JG; Lai, JC; Mehta, N; Roberts, JP; Salazar, J; Saxena, V; Volk, M	1
Hanabusa, H; Nagao, A	1
Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S	1
Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y	1
Jones, D; Massoud, O; Orr, J; Shoreibah, M; Venkata, K; Zhang, J	1
Chen, YS; Kao, JH; Liu, CH; Wang, SS	1
Aichelburg, MC; Bucsics, T; Ferenci, P; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M	1
Abdelmaksoud, A	1
Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J	1
Li, CX; Li, W; Li, ZQ; Liang, HX; Xu, GH; Yu, ZJ; Zeng, QL; Zhang, DW; Zhang, JY	1
Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA	1
Hassan, M; Lalos, A; Liriano-Ward, L; Morales, AL; Nair, V; Sang, M; Satoskar, R; Schiano, T; Smith, C; Tierney, A	1
Ahmed, A; Beckerman, R; Dieterich, D; Gordon, SC; Saab, S; Younossi, Z	1
Buti, M; Casado, MA; Domínguez-Hernández, R; Esteban, R; Oyagüez, I	1
Bergin, C; Cannon, M; Courtney, G; Crosbie, O; De Gascun, CF; Fanning, LJ; Feeney, E; Gray, E; Houlihan, DD; Kelleher, B; Lambert, JS; Lee, J; Mallon, P; McConkey, S; McCormick, A; McKiernan, S; McNally, C; Murray, F; Norris, S; O'Leary, A; Sheehan, G; Stewart, S; Walsh, C	1
Audibert, C; Livoti, C; Palak, A	1
Abo-Talib, NF; El-Ghobashy, MR; Tammam, MH	1
Alston, S; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Reau, N; Reddy, KR; Reeve, B; Sarkar, S; Sterling, RK; Stewart, P	1
Bourlière, M; Carrat, F; Carrieri, MP; Fontaine, H; Hézode, C; Marcellin, F; Petrov-Sanchez, V; Protopopescu, C; Vilotitch, A; Younossi, Z	1
El Sayed, MH; Giaquinto, C; Gonzalez-Peralta, RP; Indolfi, G; Thorne, C	1
Pullen, LC	1
Ammirati, SR; Darnell, TA; Hartis, CE; Johnson, SW; Morgan, MR; Priest, DH; Schmidlin, HN; Silwal, A; Weber, SF	1
Barocas, JA; Beiser, M; Gaeta, JM; León, C; Linas, BP; O'Connell, JJ	1
Bhagani, S; Boesecke, C; Brainard, DM; Dvory-Sobol, H; Hyland, RH; Ingiliz, P; Lutz, T; Nelson, M; Rockstroh, JK; Yun, C; Zheng, W	1
Griffin, SM; Johnson, SW; Teachey, AL; Valanejad, SM; Weber, SF	1
D'Avolio, A; D'Offizi, G; De Nicolò, A; Garbuglia, AR; Montalbano, M; Taibi, C; Tempestilli, M	1
Heil, EL; Hoke, KS; Mattingly Ii, TJ	1
Bailey, R; Borgia, S; Brainard, DM; Cooper, C; Elkhashab, M; Feld, JJ; Greenbloom, S; Huang, KC; Huchet, E; Hyland, RH; Marotta, P; Massetto, B; McHutchison, JG; Ramji, A; Shafran, SD; Svarovskaia, ES; Swain, MG; Tam, E; Vachon, ML; Willems, B; Yoshida, EM; Yun, C	1
Cheng, PN; Chiu, YC; Sun, HY; Tsai, WJ; Tseng, CY; Young, KC	1
McEwan, P; Mishina, S; Wang, F; Ward, T; Webster, S; Wygant, G	1
Sise, ME	1
Burman, B; Edwards, AM; Kozarek, RA; Lee, H; Shin, HP; Siddique, A; Wang, C; Zehr, T; Zeigler, A	1
Aikata, H; Chayama, K; Daijo, K; Hayes, CN; Honda, F; Honda, Y; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Miki, D; Mori, N; Morio, K; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Takaki, S; Teraoka, Y; Tsuge, M; Tsuji, K	1
Caruso, V; Cenderello, G; Copetti, M; Forni, G; Gamberini, R; Ganga, R; Mangia, A; Piazzolla, V; Piga, A; Quarta, A; Santoro, R; Sarli, R	1
Goda, Y; Hakamatsuka, T; Hosoe, J; Kamakura, H; Maruyama, T; Masada, S; Tokumoto, H; Tsujimoto, T; Uchiyama, N	1
Aschenbrenner, DS	1
Abaalkhail, F; Ajlan, A; Al Sebayel, M; Al-Hamoudi, W; Al-Jedai, A; Alabbad, S; Broering, D; Elbeshbeshy, H; Elsiesy, H; Saab, S; Shawkat, M; Ullah, W; Yousif, S	1
Connolly, MP; Kotsopoulos, N; Ustianowski, A	1
Baz, M; Harris, DD; Shafii, AE	1
Guedj, J; Kohli, A; Kottilil, S; Nguyen, THT; Perelson, AS; Uprichard, SL	1
Kim, HJ; Lee, HW; Won, JW; Yoo, KY	1
Fukuda, H; Fukuda, S; Irie, M; Kunimoto, H; Morihara, D; Sakamoto, K; Sakisaka, S; Shakado, S; Takata, K; Takeyama, Y; Tanaka, T; Umeda, K; Yamauchi, R; Yokoyama, K	1
Huang, JW; Liao, HT; Tan, P; Yuan, KF	1
Jindracek, L; Stark, J	1
Balistreri, W; Bansal, S; Hunt, S; Murray, KF; Rosenthal, P; Schwarz, K; Stepanova, M; Younossi, ZM	1
Beumont, M; Bourgeois, S; Hillewaert, V; Horsmans, Y; Luo, D; Moreno, C; Nevens, F; Ouwerkerk-Mahadevan, S; van de Logt, J; van Eygen, V; Van Remoortere, P; van Vlierberghe, H; Vijgen, L	1
Amoroso, A; Dellario, M; Dickson, C; Flores, Y; Kottilil, S; Parker, A; Tang, L; Wilson, E	1
Abergel, A; Asselah, T; Brainard, DM; Camus, G; Dvory-Sobol, H; Han, B; Hsieh, D; Kersey, K; Lu, J; Martin, R; Miller, MD; Mo, H; Parhy, B; Svarovskaia, E	1
Fulco, PP; Lavoie, SR; Sterling, RK	1
Aburawash, A; Elsisi, GH; Waked, E	1
Ikeda, A; Ikeda, K; Inagaki, N; Kokuryu, H; Marusawa, H; Seno, H; Takahashi, K; Takai, A; Ueda, Y	1
Brown, AN; Drusano, GL; Li, E; Liu, L; Neely, MN; Rodriquez, JL; Schuster, L; Wang, GP; Yamada, W; Zhao, L	1
Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH	1
Bruzzone, B; Canepa, P; Icardi, G; Magnani, O; Rappazzo, E; Setti, M; Sticchi, L	1
Brown, RS; Camus, G; Copans, A; Ghali, P; Guyer, B; Haubrich, R; Kang, M; Luetkemeyer, AF; Mantry, PS; Ni, L; Rossaro, L; Satapathy, SK; Shen, X; Tam, E	1
Nehra, V; Rizza, SA; Temesgen, Z	1
Ferenci, P; Gschwantler, M; Gutic, E; Haltmayer, H; Kozbial, K; Laferl, H; Lang, T; Luhn, J; Moser, S; Reiberger, T; Schleicher, M; Schubert, R; Schütz, A; Schwabl, P; Schwanke, C; Steindl-Munda, P	1
Brainard, DM; Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Hsu, YC; Hu, TH; Jiang, D; Knox, SJ; Liu, CJ; Lo, GH; Massetto, B; McHutchison, JG; Osinusi, A; Peng, CY; Sheen, IS; Tseng, KC; Wang, HY; Yang, JC; Yun, C	1
Crutcher, EL; Greene, EM; Lenz, DU	1
Ambrifi, M; Colafigli, M; Cristaudo, A; Latini, A; Orsini, D; Zaccarelli, M	1
Birkemose, I; Christensen, PB; Ernst, A; Holm, DK; Krarup, H; Mössner, B; Øvrehus, ALH	1
Agarwal, K; Carey, I; Lampejo, T	1
Fiel, MI; Putra, J; Schiano, TD	1
Chevaliez, S; Fourati, S; Francois, M; Guedj, J; Hézode, C; Mallat, A; Nguyen, THT; Pawlotsky, JM; Poiteau, L; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A	1
Fujita, K; Masaki, T; Morishita, A; Nomura, T; Oura, K; Sakamoto, T; Tadokoro, T; Tani, J; Yoneyama, H	1
Andres, J; Lott, S; Qureshi, K	1
Chamorro-de-Vega, E; Gimenez-Manzorro, A; Sanjurjo, M	1
Asahina, Y; Brainard, DM; Dvory-Sobol, H; Enomoto, N; Genda, T; Ikeda, F; Itoh, Y; Jiang, D; Kawada, N; Massetto, B; Matsuda, T; Matsuzaki, Y; McHutchison, JG; Osinusi, AO; Takikawa, Y; Ueno, Y; Yatsuhashi, H	1
Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT	1
Dohmen, K; Ichiki, Y; Ishibashi, H; Kawano, A; Miki, K; Morita, C; Nomura, H; Shigematsu, H; Shimoda, S; Takahashi, K; Yanagita, K	1
Enomoto, M; Kawada, N; Tamori, A; Tateishi, C; Tsuruta, D	1
Attia, D; Ayoub, H; El Sheemy, RY; El-Khayat, HR; El-Sayed, MH; El-Shabrawi, M; Fouad, YM; Kamal, EM; Maher, M; RizK, A	1
Asensi-Diez, R; Del Rio-Valencia, JC; Madera-Pajin, R; Muñoz-Castillo, I; Yunquera-Romero, L	1
Scott, LJ	1
Imnadze, T; Mikadze, I; Vashakidze, E	1
Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P	1
Abrams, GA; Gade, AR; Patel, M; West, DR	1
Bergmann, OM; Björnsson, ES; Fridriksdottir, RH; Gottfredsson, M; Gudnason, T; Hansdottir, I; Heimisdottir, M; Hellard, M; Johannsson, B; Löve, A; Löve, TJ; Olafsson, S; Runarsdottir, V; Sigurdardottir, B; Tyrfingsson, T	1
Cherian, R; Driscoll, C; Genther, K; Goode, MB; Lee, H; Lewis, S; Luketic, VA; Martin, K; Matherly, S; Patel, V; Puri, P; Sanyal, AJ; Siddiqui, MS; Smith, P; Sterling, RK; Stravitz, RT	1
Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE	1
Aoufi-Rabih, S; Fabrizi, F; García-Agudo, R; González-Corvillo, C; Salgueira-Lazo, M	1
Abe, H; Arai, T; Atsukawa, M; Hayama, K; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kawamoto, C; Kondo, C; Kumada, T; Nakagawa-Iwashita, A; Okubo, T; Shimada, N; Tanaka, Y; Toyoda, H; Tsubota, A	1
Brainard, DM; Camus, G; Cheng, J; Duan, Z; Gao, Y; Gong, G; Hou, JL; Hu, P; Jia, J; Jiang, J; Li, J; McNabb, B; Mo, H; Mou, Z; Nan, Y; Ning, Q; Osinusi, A; Tang, H; Wang, G; Wei, L; Wu, S; Xie, Q; Zhang, F; Zhang, L	1
Brainard, DM; German, P; Kearney, BP; Mathias, A	1
Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T	1
Jung, J; Kirchner, VA; Kwon, JH; Lee, SG; Song, GW; Tak, EY	1
AbdElgawad, MMAH; El-Khayat, HR; El-Shabrawi, MHF; Kamal, EM; Kamal, NM; Yakoot, M	1
Reinke, T	1
Aghemo, A; Aglitti, A; Andreone, P; Boccaccio, V; Bollani, S; Brunetto, MR; Bruno, S; Calvaruso, V; Ciancio, A; Coco, B; Conti, F; Degasperi, E; Di Leo, A; Di Marco, V; Giorgini, A; Lampertico, P; Lleo, A; Maisonneuve, P; Marzi, L; Persico, M; Rendina, M; Troshina, G; Villa, E; Zuin, M	1
Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM	1
Anderson, PL; Brainard, DM; Bushman, LR; Castillo-Mancilla, JR; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; MacBrayne, CE; Marks, KM; Naggie, S; Peters, MG; Seifert, SM	1
Huq, M; Jacques, K; Krasner, C; Mambourg, SE; Mikolas, LA	1
Boldt, M; Hassan, MA; Huepfel, W; Lake, JR; Shaukat, AP; Tierney, AR; Wang, Q	1
Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Inada, Y; Kasai, A; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Tabu, K; Tamai, T; Taniyama, O; Uto, H	1
Bhamidimarri, KR; Chu, D; Han, SB; Hu, KQ; Lee, TP; Ma, X; Mohanty, SR; Pan, CQ; Park, J; Tiongson, BC; Tong, M; Wang, D; Xiao, PY	1
Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I	1
Agüero, J; Alvarez, S; Ayesa, R; Cabezas, J; Calleja, JL; Chueca, N; Cobo, C; Crespo, J; Crespo-Facorro, B; Cuadrado, A; Echevarría, S; Fortea, JI; Garcia, F; Llerena, S; Lopez-Hoyos, M; Mateo, M; Pallás, JR; Pellón, R; Setién, E	1
Alper, CJ; Clements, K; Greenwood, BC; Hydery, T; Jeffrey, PL; Kouris, G; Lavitas, P; Lenz, K; Price, M	1
Chandraker, AK; Cohen, DJ; Ding, Y; Murakami, N; Rennke, HG	1
Chu, TC; Fasanmi, EO; MacDonald, BR; Moore, JD; Ojha, RP; Stewart, RA	2
Abd Alla, MDA; Al-Azhari, SS; Dawood, RM; El Awady, MK; Elhawary, MA; Galal, AGM	1
Abd Elaziz, D; Aiuti, A; Appleby, J; Barzaghi, F; Bernardo, ME; Boeri, E; Calbi, V; Calzatini, F; Canarutto, D; Casiraghi, M; Cestone, E; Cicalese, MP; Ciceri, F; Consiglieri, G; Darin, S; Dionisio, F; Ferrua, F; Finazzi, R; Gabaldo, M; Lucano, C; Marktel, S; Mieli-Vergani, G; Migliavacca, M; Recupero, S; Tucci, F	1
Boeker, KHW; Buggisch, P; Günther, R; Hüppe, D; Maasoumy, B; Manns, MP; Mauss, S; Müller, T; Sarrazin, C; Vermehren, J; Wedemeyer, H; Zimmermann, T	1
El-Shorbagy, HI; Elbrashy, AM; Elsebaei, F; Hammad, SF	1
Ladino, M; Roth, D	1
Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S	1
Gonçalves, CAM; Horta, AMLMFCA; Marques, MSC; Méndez, MJV; Sarmento-Castro, RMDR; Soeiro, CASP; Tavares, APRA	1
Cabello, V; Juampérez, J; Julio, E; Mercadal-Hally, M; Quintero, J; Rodrigo, C; Segarra, Ó; Soler-Palacín, P	1
Herrera, JL; Marshall, MC	1
Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N	1
Chua, JV; Claeys, K; Heil, EL; Hynicka, LM; Vega, AD	1
Abdullatif, H; Baroudy, S; El-Karaksy, H; El-Koofy, N; El-Raziky, MS; El-Shabrawi, M; Ghita, H; Ghobrial, C; Mogahed, EA; Okasha, S	1
Abdel Aziz, H; Ahmed Mohamed, A; Eysa, B; Fouad, HM; Rabea, M; Sabry, M	1
Abdelsameea, E; Essa, M; Sabry, A; Salama, M; Tharwa, ES	1
Aziz, A; Durazo, F; Hanna, RM; Latt, N; Mikhail, MM; Mitry, A; Saab, S; Sahota, A; Yanny, B	1
Dupuy, CA; Glotz, D; Parlati, L; Pol, S; Sirmai, L	1
Abdullatif, H; El-Karaksy, H; Ghobrial, C; Mogahed, E; Sobhy, R	1
Cicchetti, A; De Solda, F; Drago, C; Kondili, LA; Nappi, C; Rolli, FR; Ruggeri, M	1
Brooks-Rooney, C; Chen, CY; Chen, JJ; Cheng, PN; Hsieh, TY; Huang, YH; Kao, JH; Lin, CL; Liu, CH; Lo, CC; Ma, Q; Peng, CY; Su, WW; Yu, ML	1
Chen, EQ; Lv, DD; Tang, H; Tao, YC; Wang, ML; Wu, DB; Zhang, DM	1
Morrison, C	1
Adamek, B; Baka-Ćwierz, B; Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracki, W; Dybowska, D; Flisiak, R; Garlicki, A; Gietka, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Laurans, Ł; Lorenc, B; Mazur, W; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D	1
Castellano Tortajada, G; Fernández Vázquez, I; Gómez Domínguez, E; Ibarrola de Andrés, C; López Couceiro, L; Muñoz Gómez, R	1
Do, A; Do, S; Levitt, B; Nguyen, E; Nguyen, H; Nguyen, K; Nguyen, M; Nguyen, MH; Purohit, T; Shieh, E; Trinh, H; Trinh, S	1
Chin, B; Khattak, MA; Menon, LL	1
Arends, JE; Boerekamps, A; Dofferhoff, ASM; Florence, E; Koopsen, J; Posthouwer, D; Ramsoekh, D; Rijnders, BJ; Schinkel, J; van den Berk, GE; van der Valk, M; van Hoek, B; van Kasteren, M; Vanwolleghem, T	1
Aboufarrag, GA; Lashen, SA; Madkour, MA; Shamseya, MM	1
Camus, G; Damascene, MJ; Grant, PM; Gupta, N; Kabahizi, J; Kateera, F; Mbituyumuremyi, A; Mukabatsinda, C; Mukherjee, J; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Ntaganda, F; Ntirenganya, C; Shumbusho, F; Van Nuil, JI	1
Alcazer, V; Charre, C; Cotte, L; Miailhes, P; Ramière, C	1
Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC	2
Attia, D; El Shabrawi, M; El-Khayat, H; Fouad, Y; Gawad, MA; Haseeb, A; Kamal, EM; Kamal, N; Sameh, Y; Yakoot, M	1
Barker, L; Jiles, RB; White, JZ; Yin, S	1
Akarca, US; Akdogan, M; Akhan, S; Aladag, M; Ataseven, H; Cakaloglu, Y; Cavus, B; Demir, M; Erol, C; Ersoz, G; Gunduz, F; Gunsar, F; Idilman, R; Iliaz, R; Karasu, Z; Kaymakoglu, S; Kiyici, M; Koklu, H; Koksal, AS; Koksal, İ; Ozgenel, M; Sahin, M; Tabak, F; Turan, İ	1
Apple, DB; Burke, MT; Hu, JK; Lin, X; Padidam, S	1
Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K	1
Aldir, I; Bana E Costa, T; Carvalho, A; Chagas, C; Correia, JM; Falcão, F; Farinha, H; Lebre, L; Lopes, C; Mansinho, K; Marques, S; Miranda, AC; Mirco, A; Peixe, P; Perez, R; Viegas, E	1
Birerdinc, A; Curry, MP; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Stepanova, M; Weinstein, AA; Younossi, ZM	1
Behar, E; Coffin, PO; Fox, R; Hern, J; Kinnard, EN; Matheson, T; Page, K; Santos, GM; Silvis, J; Vittinghoff, E; Walker, J	1
Brainard, DM; Chung, RT; Fierer, DS; Hughes, MD; Kim, AY; Kiser, JJ; Luetkemeyer, A; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Rwema, S; Vu, V	1
Balistreri, WF; Bansal, S; Brainard, DM; Hague, R; Hardikar, W; Honegger, JR; Hsueh, CH; Massetto, B; Mittal, N; Murray, KF; Narkewicz, MR; Parhy, B; Rao, GS; Rosenthal, P; Schwarz, KB; Shao, J; Whitworth, S	1
Abdullatif, HM; El Rasheed Abd El Zaher, BA; El Raziky, MS; El-Karaksy, HM; Ghobrial, CM; Mogahed, EA; Ramzi, R	1
Anan, A; Inomata, S; Irie, M; Kunimoto, H; Morihara, D; Sakisaka, S; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Yamauchi, E; Yamauchi, R; Yokoyama, K	1
Aizaki, H; Hatanaka, T; Hmwe, SS; Hoshino, T; Kakizaki, S; Naganuma, A; Sato, K; Tateyama, Y; Uraoka, T; Wakita, T; Yoshinari, F	1
Abdel Aziz, H; Ahmed, A; Al Soda, MF; Fouad, HM; Hassany, M; Sabry, MA	1
Bartolini, E; Cangelosi, AM; D'Antiga, L; Dodi, I; Indolfi, G; Mastrangelo, G; Nicastro, E; Resti, M; Ricci, S; Riva, S; Serranti, D; Trapani, S; Vajro, P	1
Adeline, NJF; Geue, C; Hermami, MR	1
Awad, J; Balsara, K; Brinkley, DM; Brown Sacks, S; Danter, M; Darragh, C; Fowler, R; Lindenfeld, J; Menachem, J; O'Dell, H; Ooi, H; Perri, R; Punnoose, L; Ruzevich-Scholl, S; Schlendorf, K; Shah, A; Smith, S; Wigger, M; Zalawadiya, SK	1
Birerdinc, A; Curry, M; de Avila, L; Escheik, C; Estep, JM; Gerber, L; Golabi, P; Price, JK; Stepanova, M; Weinstein, AA; Younossi, ZM	1
Abdel-Aziz, SA; Adawy, NM; Allam, AA; Ayoub, BA; Basiouny, HEDM; Behairy, BE; El-Araby, HA; El-Guindi, MA; Elhenawy, IA; Fouad, OA; Khedr, MA; Salem, ME; Sira, AM; Sobhy, GA	1
Berg, C; Eigentler, T; Forschner, A; Geipel, A; Kofler, K; Kofler, L; Lipp, HP; Müller, A	1
Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S	1
Amarsanaa, J; Baatarkhuu, O; Enkhtuya, D; Enkhzaya, S; Hsu, SJ; Ivshinkhorol, D; Jargalsaikhan, B; Kao, JH; Khosbayar, T; Lin, YY; Naranzul, N; Tsai, CH; Tseng, TC; Wang, TS	1
Alonso López, S; Guerra Romero, AR; Pérez Figueras, M	1
Chayama, K; Gonzalez, YS; Kawaguchi, I; Kumada, H; Mitchell, D; Virabhak, S; Yuen, C	1
Chaikledkaew, U; Due, OT; Genuino, AJM; Sobhonslidsuk, A; Thakkinstian, A	1
Farcomeni, A; Gioia, S; Nardelli, S; Ridola, L; Riggio, O; Rosati, D	1
Lazarus, JV; Lens, S	1
Ayoub, BA; Basiouny, HM; Behairy, BE; El-Araby, HA; El-Guindi, MA; Fouad, OA; Marei, AM; Sira, MM	1
Althoff, KN; Elion, RA; Eron, JJ; Gillman, J; Huhn, GD; Jayaweera, DT; Mills, A; Mounzer, K; Moyle, G; Patel, SV; Radtchenko, J; Santiago, S; Sax, PE	1
Alloway, RR; Eckman, MH; Sherman, KE; Thakar, CV; Woodle, ES	1
Sirinawasatien, A; Techasirioangkun, T	1
Banga, J; Nagarakanti, S; Nizami, S; Portilla, M; Slim, J; Swaminathan, S	1
Day, J; Le, HM; Le, PT; Nghiem, NM; Nguyen, DT; Rahman, M; Tran, TTT; Vo, QM	1
Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C	1
Barclay, ST; de Bruin, M; Dillon, JF; Donnan, PT; Fraser, A; Hapca, A; Inglis, SK; Radley, A	1
Bonacini, M; Brainard, DM; De-Oertel, S; Flamm, SL; Gane, EJ; Gordon, SC; Huang, J; Hyland, RH; Kirby, BJ; Landis, CS; Lawitz, E; Maliakkal, BJ; Ortiz-Lasanta, G; Osinusi, AO; Robson, R; Zhang, J	1
Abd-Elsalam, S; Abdellatif, RS; Abo-Amer, YE; Elbedewy, TA; Elsebaey, MA; Fouad, A; Mostafa, SM; Youssef, M	1
Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA	1
Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML	1
AlBayati, SM; Faraj, OA	1
Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI	1

Reviews

77 review(s) available for uridine monophosphate and sofosbuvir

Article	Year
The HCV NS5B nucleoside and non-nucleoside inhibitors. Clinics in liver disease, 2011, Volume: 15, Issue:3 Topics: Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Guanosine Monophosphate; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2011
Interferon free hepatitis C treatment regimens: the beginning of another era. Current gastroenterology reports, 2012, Volume: 14, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate	2012
Treatment of chronic hepatitis C--are interferons really necessary? Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Carbamates; Cyclophilins; Cyclosporine; Drug Substitution; Hepatitis C, Chronic; Humans; Imidazoles; Immunologic Factors; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Serine Proteinase Inhibitors; Sofosbuvir; Uridine Monophosphate; Valine	2012
What's new in HCV genotype 2 treatment. Liver international : official journal of the International Association for the Study of the Liver, 2012, Volume: 32 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2012
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR. Clinics in liver disease, 2013, Volume: 17, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate	2013
Nucleoside/nucleotide analogue polymerase inhibitors in development. Clinics in liver disease, 2013, Volume: 17, Issue:1 Topics: Cytidine; Deoxycytidine; Drugs, Investigational; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Protein Conformation; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2013
Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:4 Topics: Antiviral Agents; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Nucleotidyltransferases; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2013
Sofosbuvir and ABT-450: terminator of hepatitis C virus? World journal of gastroenterology, 2013, Jun-07, Volume: 19, Issue:21 Topics: Animals; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Hepatitis Viruses; Humans; Interferons; Interleukins; Lactams, Macrocyclic; Macrocyclic Compounds; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Proline; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2013
A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Current medicinal chemistry, 2013, Volume: 20, Issue:30 Topics: Administration, Oral; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2013
Emerging treatments for hepatitis C. Expert opinion on emerging drugs, 2013, Volume: 18, Issue:4 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2013
Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert review of anti-infective therapy, 2013, Volume: 11, Issue:12 Topics: Antiviral Agents; Biomarkers, Pharmacological; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2013
New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut, 2014, Volume: 63, Issue:2 Topics: Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Prodrugs; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Sofosbuvir for the treatment of hepatitis C virus. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:1 Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Hepacivirus; Hepatitis C; Sofosbuvir; Uridine Monophosphate; Virus Physiological Phenomena	2014
Treatment of hepatitis C virus genotype 3-infection. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sofosbuvir; Standard of Care; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Viral Proteins	2014
Management of HCV patients with cirrhosis with direct acting antivirals. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate	2014
Treating HCV in HIV 2013: on the cusp of change. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine	2014
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate	2014
HCV direct-acting antiviral agents: the best interferon-free combinations. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication	2014
HCV F1/F2 patients: treat now or continue to wait. Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34 Suppl 1 Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate	2014
Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:5 Topics: Antiviral Agents; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Sofosbuvir: first global approval. Drugs, 2014, Volume: 74, Issue:2 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Sofosbuvir (Sovaldi) for chronic hepatitis C. The Medical letter on drugs and therapeutics, 2014, Jan-20, Volume: 56, Issue:1434 Topics: Animals; Clinical Trials as Topic; Hepatitis C, Chronic; Humans; Prodrugs; Sofosbuvir; Uridine Monophosphate	2014
Hepatitis C virus therapy in the direct acting antiviral era. Current opinion in gastroenterology, 2014, Volume: 30, Issue:3 Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate	2014
Hepatitis C treatment: an incipient therapeutic revolution. Trends in molecular medicine, 2014, Volume: 20, Issue:6 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Molecular Targeted Therapy; Oligopeptides; Proline; Protease Inhibitors; Sofosbuvir; Uridine Monophosphate	2014
Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clinical pharmacokinetics, 2014, Volume: 53, Issue:5 Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
The rapid evolution of treatment strategies for hepatitis C. The American journal of gastroenterology, 2014, Volume: 109, Issue:5 Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2014
Interferon-free strategies with a nucleoside/nucleotide analogue. Seminars in liver disease, 2014, Volume: 34, Issue:1 Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Design; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Targeted Therapy; Nucleosides; Nucleotides; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2014
The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection. JAMA internal medicine, 2014, Volume: 174, Issue:7 Topics: Antiviral Agents; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert opinion on investigational drugs, 2014, Volume: 23, Issue:9 Topics: Animals; Antiviral Agents; Disease Progression; Drug Design; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
Hepatitis C. Disease-a-month : DM, 2014, Volume: 60, Issue:5 Topics: Adult; Age Distribution; Anti-HIV Agents; Communicable Disease Control; Disease Management; Female; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Needs Assessment; Prisoners; Prisons; Ribavirin; Risk Assessment; Sex Distribution; Simeprevir; Sofosbuvir; Sulfonamides; Telemedicine; Treatment Outcome; United States; Uridine Monophosphate; Young Adult	2014
Daclatasvir for the treatment of hepatitis C virus infection. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:7 Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine	2014
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert review of anti-infective therapy, 2014, Volume: 12, Issue:7 Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine	2014
Sofosbuvir (Sovaldi) for the treatment of hepatitis C. Expert review of clinical pharmacology, 2014, Volume: 7, Issue:5 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs, 2014, Volume: 74, Issue:10 Topics: Antiviral Agents; Enzyme Inhibitors; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Sofosbuvir for the treatment of chronic hepatitis C virus infection. Drugs of today (Barcelona, Spain : 1998), 2014, Volume: 50, Issue:6 Topics: Administration, Oral; Animals; Antiviral Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Patient Safety; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Antiviral treatment of hepatitis C. BMJ (Clinical research ed.), 2014, Jul-07, Volume: 348 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. International journal of antimicrobial agents, 2014, Volume: 44, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Middle Aged; Recurrence; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult	2014
Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus. The Journal of pharmacy and pharmacology, 2014, Volume: 66, Issue:12 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus. Current opinion in virology, 2014, Volume: 9 Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Humans; Nucleosides; Nucleotides; RNA Viruses; RNA, Viral; Sofosbuvir; Uridine Monophosphate	2014
Recent advances and future directions in the management of hepatitis C infections. Pharmacology & therapeutics, 2015, Volume: 145 Topics: Animals; Antiviral Agents; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uridine Monophosphate	2015
Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jan-01, Volume: 60, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Liver Transplantation; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2015
Hepatitis C genotype 1. Current opinion in infectious diseases, 2014, Volume: 27, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load	2014
Update on the treatment of hepatitis C genotypes 2-6. Current opinion in infectious diseases, 2014, Volume: 27, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Load	2014
Recent advances in the treatment of hepatitis C. Discovery medicine, 2014, Volume: 18, Issue:99 Topics: Animals; Antiviral Agents; Carrier Proteins; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era. The Netherlands journal of medicine, 2014, Volume: 72, Issue:8 Topics: Antiviral Agents; Clinical Trials as Topic; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Practice Guidelines as Topic; Protease Inhibitors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Hepatitis C management in post-transplant patients. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load	2015
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:47 Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine	2014
Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. Journal of hepatology, 2014, Volume: 61, Issue:1 Suppl Topics: Antiviral Agents; DNA, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Sofosbuvir as backbone of interferon free treatments. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis D, Chronic; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Quality of Life; Randomized Controlled Trials as Topic; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2014
The evolution of the therapeutic strategy in hepatitis C: features of sofosbuvir and indications. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5 Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Virus Replication	2014
Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Dec-15, Volume: 46 Suppl 5 Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate	2014
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3 Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viral Nonstructural Proteins	2015
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1 Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine	2015
Optimal therapy of genotype-2 chronic hepatitis C: what's new? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1 Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prevalence; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1 Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins	2015
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35 Suppl 1 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Precision Medicine; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine	2015
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C. Expert opinion on drug safety, 2015, Volume: 14, Issue:3 Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Meta-Analysis as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2015
Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series. Postgraduate medicine, 2015, Volume: 127, Issue:4 Topics: Administration, Oral; Adult; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate	2015
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals]. Orvosi hetilap, 2015, May-24, Volume: 156, Issue:21 Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication	2015
Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert opinion on drug safety, 2015, Volume: 14, Issue:8 Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate	2015
Management of direct-acting antiviral agent failures. Journal of hepatology, 2015, Volume: 63, Issue:6 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine	2015
The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. Current opinion in infectious diseases, 2015, Volume: 28, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Design; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Uridine Monophosphate	2015
Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties. Prescrire international, 2015, Volume: 24, Issue:166 Topics: Animals; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate	2015
Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective. PharmacoEconomics, 2016, Volume: 34, Issue:8 Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Time Factors; Uridine Monophosphate	2016
Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. Clinical pharmacokinetics, 2016, Volume: 55, Issue:11 Topics: Animals; Antiviral Agents; Area Under Curve; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Half-Life; Hepatitis C, Chronic; Humans; Hydrogen-Ion Concentration; Liver Failure; Metabolic Clearance Rate; Renal Insufficiency; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2016
Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:1 Topics: Animals; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate	2017
The Challenge of Treating Children With Hepatitis C Virus Infection. Journal of pediatric gastroenterology and nutrition, 2017, Volume: 64, Issue:6 Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate	2017
Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis. Transplantation proceedings, 2017, Volume: 49, Issue:8 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate	2017
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load	2018
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs, 2018, Volume: 78, Issue:2 Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. Clinical pharmacokinetics, 2018, Volume: 57, Issue:11 Topics: Benzimidazoles; Drug Interactions; Fluorenes; Humans; Sofosbuvir; Uridine Monophosphate	2018
Cost-effectiveness of treating hepatitis C in Seychelles. The Pan African medical journal, 2019, Volume: 33 Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Markov Chains; Quality-Adjusted Life Years; Sex Factors; Seychelles; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate	2019
Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6. BioMed research international, 2019, Volume: 2019 Topics: Antiviral Agents; Benzimidazoles; Databases, Factual; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Uridine Monophosphate	2019

Trials

87 trial(s) available for uridine monophosphate and sofosbuvir

Article	Year
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. Journal of hepatology, 2013, Volume: 58, Issue:4 Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult	2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. The New England journal of medicine, 2013, Jan-03, Volume: 368, Issue:1 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins	2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. The Lancet. Infectious diseases, 2013, Volume: 13, Issue:5 Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Nausea; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Secondary Prevention; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult	2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883 Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Puerto Rico; Recombinant Proteins; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate	2013
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult	2013
Sofosbuvir for previously untreated chronic hepatitis C infection. The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20 Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Young Adult	2013
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA, 2013, Aug-28, Volume: 310, Issue:8 Topics: Antiviral Agents; Body Weight; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Prognosis; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2013
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). Journal of viral hepatitis, 2013, Volume: 20, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult	2013
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. The Journal of infectious diseases, 2014, Mar-01, Volume: 209, Issue:5 Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916 Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology, 2014, Volume: 146, Issue:3 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Fatigue; Female; Fluorenes; Furans; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Middle Aged; Nausea; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). Journal of hepatology, 2014, Volume: 60, Issue:4 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mental Health; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. The Journal of infectious diseases, 2014, Jun-01, Volume: 209, Issue:11 Topics: Antiviral Agents; Gene Expression Regulation; Genetic Predisposition to Disease; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. The New England journal of medicine, 2014, Jan-16, Volume: 370, Issue:3 Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Young Adult	2014
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938. Antiviral therapy, 2014, Volume: 19, Issue:2 Topics: Adult; Antiviral Agents; Cyclic P-Oxides; Double-Blind Method; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Nucleosides; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult	2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. Journal of hepatology, 2014, Volume: 61, Issue:2 Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult	2014
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. The New England journal of medicine, 2014, Apr-17, Volume: 370, Issue:16 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nucleotidyltransferases; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins	2014
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. The New England journal of medicine, 2014, May-15, Volume: 370, Issue:20 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult	2014
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. The New England journal of medicine, 2014, May-22, Volume: 370, Issue:21 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load	2014
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. The Journal of clinical investigation, 2014, Volume: 124, Issue:8 Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Endopeptidases; Gene Expression; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Recurrence; Ribavirin; RNA, Messenger; Sofosbuvir; Treatment Outcome; Ubiquitin Thiolesterase; Uridine Monophosphate	2014
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:10 Topics: Adult; Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine	2014
Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6 Topics: Adolescent; Antiviral Agents; Drug Therapy, Combination; Female; Health Surveys; Hepatitis C, Chronic; Humans; Interferons; Male; Patient Preference; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Uridine Monophosphate	2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet (London, England), 2014, Nov-15, Volume: 384, Issue:9956 Topics: Adult; Antiviral Agents; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2014
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11 Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. Journal of viral hepatitis, 2014, Volume: 21, Issue:11 Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult	2014
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3 Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Lipoproteins, LDL; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Virus Replication	2015
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology, 2015, Volume: 148, Issue:1 Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists	2015
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Dec-15, Volume: 59, Issue:12 Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hepacivirus; High-Throughput Nucleotide Sequencing; Humans; Male; Phenotype; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology, 2015, Volume: 148, Issue:1 Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load	2015
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:1 Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Recurrence; RNA, Viral; Sofosbuvir; Uridine Monophosphate	2015
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Annals of internal medicine, 2014, Nov-04, Volume: 161, Issue:9 Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate	2014
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5 Topics: Antiviral Agents; Compassionate Use Trials; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Failure; Uridine Monophosphate	2015
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology, 2015, Volume: 148, Issue:4 Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Viral Load	2015
Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. The Journal of infectious diseases, 2015, Aug-01, Volume: 212, Issue:3 Topics: Antiviral Agents; Coinfection; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Quality of Life; Ribavirin; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973 Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load	2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:4 Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Time Factors; Uridine Monophosphate; Valine; Young Adult	2015
Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV. Journal of acquired immune deficiency syndromes (1999), 2015, Apr-15, Volume: 68, Issue:5 Topics: Adult; Aged; Animals; Anti-Retroviral Agents; Antiviral Agents; Cohort Studies; Drug Interactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2015
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6 Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973 Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult	2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). The Lancet. Infectious diseases, 2015, Volume: 15, Issue:4 Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Double-Blind Method; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Placebos; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult	2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate	2015
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult	2015
Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1 Topics: Adult; Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Failure; Uridine Monophosphate; Young Adult	2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult	2015
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology (Baltimore, Md.), 2015, Volume: 62, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate; Young Adult	2015
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, Volume: 149, Issue:3 Topics: Antiviral Agents; Benzimidazoles; Cholestasis, Intrahepatic; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate	2015
[Healing rate after 12 weeks over 90% for the first time]. MMW Fortschritte der Medizin, 2015, Apr-02, Volume: 157, Issue:6 Topics: Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine	2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine, 2015, Aug-20, Volume: 373, Issue:8 Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Valine; Viral Load	2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. The New England journal of medicine, 2015, Aug-20, Volume: 373, Issue:8 Topics: Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load	2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult	2016
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS research and human retroviruses, 2016, Volume: 32, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate	2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antiviral therapy, 2016, Volume: 21, Issue:6 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load	2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet. Infectious diseases, 2016, Volume: 16, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Global Health; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load	2016
A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatology international, 2016, Volume: 10, Issue:6 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Republic of Korea; Sofosbuvir; Sustained Virologic Response; Tablets; Treatment Outcome; Uridine Monophosphate; Young Adult	2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. Gastroenterology, 2016, Volume: 151, Issue:3 Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins	2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir. Journal of hepatology, 2017, Volume: 66, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Mutation; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Viral Nonstructural Proteins	2017
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). The patient, 2017, Volume: 10, Issue:5 Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Comorbidity; Double-Blind Method; Female; Fluorenes; Health Status; Hepatitis C, Chronic; Humans; Male; Mental Health; Middle Aged; Oligopeptides; Patient Reported Outcome Measures; Polyethylene Glycols; Proline; Quality of Life; Severity of Illness Index; Sex Factors; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. The lancet. Gastroenterology & hepatology, 2017, Volume: 2, Issue:5 Topics: Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Administration Schedule; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jul-01, Volume: 65, Issue:1 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2017
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:4 Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Thalassemia; Treatment Failure; Uridine Monophosphate	2017
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics? Scientific reports, 2017, 08-31, Volume: 7, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Models, Theoretical; Quinolines; Sofosbuvir; Sustained Virologic Response; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. Journal of pediatric gastroenterology and nutrition, 2018, Volume: 66, Issue:1 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Caregivers; Child; Female; Fluorenes; Follow-Up Studies; Health Status Indicators; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Quality of Life; Self Report; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:12 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Photosensitivity Disorders; Simeprevir; Sofosbuvir; Solute Carrier Organic Anion Transporter Family Member 1B3; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Fatigue; Female; Fluorenes; Headache; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Pregnancy; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2018
Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology, 2018, Volume: 154, Issue:4 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load	2018
Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial. Journal of hepatology, 2018, Volume: 68, Issue:4 Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate	2018
Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins	2018
Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection. Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult	2018
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. Journal of internal medicine, 2018, Volume: 283, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Iceland; Incidence; Liver Cirrhosis; Liver Neoplasms; Mass Screening; Needle-Exchange Programs; Population Surveillance; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate	2018
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatology international, 2018, Volume: 12, Issue:2 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Safety; RNA, Viral; Sofosbuvir; Tablets; Treatment Outcome; Uridine Monophosphate; Young Adult	2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut, 2019, Volume: 68, Issue:4 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2019
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8 Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Ribavirin; Sofosbuvir; Tenofovir; Uridine Monophosphate	2018
Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. The American journal of gastroenterology, 2018, Volume: 113, Issue:11 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Disease Eradication; Environmental Exposure; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prisoners; Prisons; Program Evaluation; Sofosbuvir; Spain; Sustained Virologic Response; Uridine Monophosphate; Viral Load; Viremia; Young Adult	2018
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. Archives of virology, 2018, Volume: 163, Issue:10 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult	2018
Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Child; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2018
Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:9 Topics: Adult; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Prospective Studies; Ribavirin; Severity of Illness Index; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Uridine Monophosphate	2019
Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. PloS one, 2019, Volume: 14, Issue:6 Topics: Adult; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; Middle Aged; Prevalence; San Francisco; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate	2019
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 07-18, Volume: 69, Issue:3 Topics: Acute Disease; Administration, Oral; Adult; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Administration Schedule; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferons; Male; Middle Aged; Ribavirin; Sexual and Gender Minorities; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load	2019
Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents. Internal medicine (Tokyo, Japan), 2019, Oct-15, Volume: 58, Issue:20 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Ferritins; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepcidins; Humans; Iron; Iron Overload; Male; Middle Aged; Peptide Hormones; Prospective Studies; Sofosbuvir; Uridine Monophosphate	2019
Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection. Journal of the Pediatric Infectious Diseases Society, 2020, Jul-13, Volume: 9, Issue:3 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Blood Transfusion; Child; Drug Combinations; Drugs, Generic; Egypt; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Uridine Monophosphate	2020
Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection. Journal of pediatric gastroenterology and nutrition, 2019, Volume: 69, Issue:5 Topics: Adolescent; Adolescent Health Services; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Italy; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2019
Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study. Journal of neuroimmunology, 2019, 10-15, Volume: 335 Topics: Adult; Antiviral Agents; Benzimidazoles; Cognition; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neurotransmitter Agents; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:9 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Opiate Substitution Treatment; Outcome Assessment, Health Care; Pharmacists; Pyrrolidines; Scotland; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine	2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:10 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; New Zealand; Non-Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Ribavirin; Safety; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load	2020
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial. Journal of medicine and life, 2022, Volume: 15, Issue:3 Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2022

Other Studies

321 other study(ies) available for uridine monophosphate and sofosbuvir

Article	Year
Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay. ACS medicinal chemistry letters, 2021, Jan-14, Volume: 12, Issue:1 Topics:	2021
Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. The Journal of biological chemistry, 2010, Nov-05, Volume: 285, Issue:45 Topics: Antiviral Agents; Carboxylic Ester Hydrolases; Cathepsin A; Cell Line; Hepacivirus; Hepatocytes; Humans; Hydrolysis; Nucleoside-Phosphate Kinase; Prodrugs; RNA, Viral; Sofosbuvir; Stereoisomerism; Uridine Monophosphate; Viral Nonstructural Proteins; Virus Replication	2010
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. Journal of medicinal chemistry, 2010, Oct-14, Volume: 53, Issue:19 Topics: Animals; Antiviral Agents; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Viral; Esters; Hepacivirus; Hepatocytes; Humans; In Vitro Techniques; Liver; Macaca fascicularis; Mutation; Prodrugs; Rats; Replicon; Sofosbuvir; Stereoisomerism; Structure-Activity Relationship; Uridine Monophosphate; Viral Nonstructural Proteins	2010
Synthesis of diastereomerically pure nucleotide phosphoramidates. The Journal of organic chemistry, 2011, Oct-21, Volume: 76, Issue:20 Topics: Amides; Amino Acids; Antiviral Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; DNA-Directed RNA Polymerases; Electrons; Esters; Hepacivirus; Hepatitis C; Humans; Magnetic Resonance Spectroscopy; Nucleosides; Nucleotides; Phenols; Phosphoric Acids; Prodrugs; Sofosbuvir; Stereoisomerism; Structure-Activity Relationship; Uridine Monophosphate; Viral Proteins	2011
Synthesis of stable isotope labeled analogs of the anti-hepatitis C virus nucleotide prodrugs PSI-7977 and PSI-352938. Nucleosides, nucleotides & nucleic acids, 2011, Volume: 30, Issue:11 Topics: Antiviral Agents; Cyclic P-Oxides; Halogenation; Hepacivirus; Hepatitis C; Humans; Isotope Labeling; Nucleosides; Prodrugs; Sofosbuvir; Uridine Monophosphate	2011
Trial watch: an all-oral and interferon-free future for HCV therapy? Nature reviews. Drug discovery, 2011, Dec-01, Volume: 10, Issue:12 Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Forecasting; Hepatitis C; Humans; Interferons; Nucleic Acid Synthesis Inhibitors; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2011
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Antiviral Agents; Cell Line; Genotype; Hepacivirus; Humans; Replicon; Sofosbuvir; Uridine Monophosphate; Virus Replication	2012
Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:4 Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Congresses as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Interleukins; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins	2013
Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. The protein journal, 2013, Volume: 32, Issue:1 Topics: Amino Acid Sequence; Antiviral Agents; Catalytic Domain; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Models, Molecular; Molecular Sequence Data; Sequence Alignment; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2013
Sofosbuvir: the final nail in the coffin for hepatitis C? The Lancet. Infectious diseases, 2013, Volume: 13, Issue:5 Topics: Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate	2013
Hepatitis C treatment: interferon free or interferon freer? Lancet (London, England), 2013, Jun-15, Volume: 381, Issue:9883 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate	2013
Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2013, Volume: 13, Issue:6 Topics: Carbamates; Cholestasis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; RNA, Viral; Sofosbuvir; Transplantation, Homologous; Uridine Monophosphate; Valine	2013
HCV treatment--no more room for interferonologists? The New England journal of medicine, 2013, May-16, Volume: 368, Issue:20 Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2013
Targeted drugs to tackle hepatitis C. Nature, 2013, May-02, Volume: 497, Issue:7447 Topics: Age Factors; Carrier State; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Male; Mass Screening; Middle Aged; Molecular Targeted Therapy; Risk Assessment; Sofosbuvir; Uridine Monophosphate	2013
Trials wrap on interferon-free hepatitis C regimen. Managed care (Langhorne, Pa.), 2013, Volume: 22, Issue:4 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Hepatitis C; Humans; Interferons; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2013
All-oral HCV therapies near approval. Nature reviews. Drug discovery, 2013, Volume: 12, Issue:6 Topics: Administration, Oral; Animals; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Hepatitis Vaccines	2013
The top 10 drug trends right now. Nursing management, 2013, Volume: 44, Issue:7 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Azepines; Biphenyl Compounds; Canagliflozin; Cholesterol Ester Transfer Proteins; Dimethyl Fumarate; Drug Approval; Forecasting; Fumarates; gamma-Cyclodextrins; Glucosides; Humans; Lactones; Maytansine; Pyridines; Sofosbuvir; Sugammadex; Thiophenes; Trastuzumab; Triazoles; United States; United States Food and Drug Administration; Uridine Monophosphate	2013
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:2 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Chimera; Deoxycytidine; Genotype; Hepacivirus; Humans; Lead; Liver Neoplasms; Mutation; Peptide Hydrolases; Sofosbuvir; Transfection; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. British journal of pharmacology, 2014, Volume: 171, Issue:1 Topics: Antiviral Agents; Biliverdine; Carcinoma, Hepatocellular; Cell Line, Tumor; Diterpenes; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Heme Oxygenase-1; Hepacivirus; Host-Parasite Interactions; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; RNA Interference; Signal Transduction; Sofosbuvir; Time Factors; Transfection; Uridine Monophosphate; Viral Nonstructural Proteins; Virus Replication	2014
Interferon-free hepatitis C treatment: one pill to fit all? Lancet (London, England), 2014, Feb-08, Volume: 383, Issue:9916 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Ribavirin; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:8 Topics: Antiviral Agents; Efficiency; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Quality of Life; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Treatment Outcome; Uridine Monophosphate	2014
Pharmaceuticals. Advocates protest the cost of a hepatitis C cure. Science (New York, N.Y.), 2013, Dec-13, Volume: 342, Issue:6164 Topics: Antiviral Agents; Consumer Advocacy; Cost of Illness; Drug Approval; Drugs, Generic; Hepacivirus; Hepatitis C; Humans; Prevalence; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2013
Sofosbuvir approved for chronic hepatitis C infection. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2014, Jan-15, Volume: 71, Issue:2 Topics: Drug Approval; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2014
Patent battle lines drawn as sofosbuvir gains approval. Nature reviews. Drug discovery, 2014, Volume: 13, Issue:1 Topics: Drug Approval; Drug Industry; Humans; Patents as Topic; Sofosbuvir; Uridine Monophosphate	2014
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:7 Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine	2014
FDA approvals usher in the post-interferon era in HCV. Nature biotechnology, 2014, Volume: 32, Issue:1 Topics: Drug Approval; Drug Industry; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Uridine Monophosphate	2014
Incorporating patient-reported outcomes into hepatitis C virus treatment studies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:8 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Uridine Monophosphate	2014
Screening urged for hepatitis C but drug costs are prohibitive. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2014, Mar-18, Volume: 186, Issue:5 Topics: Antiviral Agents; Canada; Drug Costs; Hepatitis C; Humans; Mass Screening; Sofosbuvir; Uridine Monophosphate	2014
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:5 Topics: Antiviral Agents; Genotype; Hepacivirus; Mutation; Polymorphism, Genetic; Protein Structure, Secondary; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Hepatitis C virus: here comes all-oral treatment. Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:3 Topics: Administration, Oral; Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Protease Inhibitors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
When are effective medications just too expensive? Cleveland Clinic journal of medicine, 2014, Volume: 81, Issue:3 Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Protease Inhibitors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Hepatitis C treatment & management. Journal of medicine and life, 2014, Mar-15, Volume: 7, Issue:1 Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate	2014
A general and enantioselective approach to pentoses: a rapid synthesis of PSI-6130, the nucleoside core of sofosbuvir. Journal of the American Chemical Society, 2014, Apr-23, Volume: 136, Issue:16 Topics: Chemistry Techniques, Synthetic; Deoxycytidine; Kinetics; Pentoses; Sofosbuvir; Stereoisomerism; Substrate Specificity; Uridine Monophosphate	2014
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Liver Cirrhosis; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Retreatment; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:5 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Oligopeptides; Proline; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate	2014
Chronic viral hepatitis. Treatment progress, hopes for cures. Mayo Clinic health letter (English ed.), 2014, Volume: 32, Issue:3 Topics: Antiviral Agents; Diagnostic Imaging; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver; Serologic Tests; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
The price of good health. Nature medicine, 2014, Volume: 20, Issue:4 Topics: Antiviral Agents; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology (Baltimore, Md.), 2014, Volume: 59, Issue:6 Topics: Adult; Antiviral Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Hepatitis C could be virtually eliminated by 2030, experts believe. BMJ (Clinical research ed.), 2014, Apr-10, Volume: 348 Topics: Antiviral Agents; Disease Eradication; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate	2014
Therapy for hepatitis C--the costs of success. The New England journal of medicine, 2014, Apr-17, Volume: 370, Issue:16 Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Uridine Monophosphate	2014
Hepatitis C drugs not reaching poor. Nature, 2014, Apr-17, Volume: 508, Issue:7496 Topics: Anti-HIV Agents; Antiviral Agents; Developing Countries; Drug Costs; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate	2014
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:12 Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate	2014
Sovaldi ushers in wave of costly hepatitis C drugs. Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:1 Topics: Antiviral Agents; Fees, Pharmaceutical; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate	2014
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation. Seminars in liver disease, 2014, Volume: 34, Issue:1 Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Antiviral research, 2014, Volume: 107 Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Discovery; Fluorenes; Hepatitis C, Chronic; Humans; Nucleosides; Nucleotides; Sofosbuvir; Uridine Monophosphate	2014
The high price of the new hepatitis C virus drugs. JAMA internal medicine, 2014, Volume: 174, Issue:7 Topics: Antiviral Agents; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy. Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:1 Topics: Drug Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Activists sound alarm on tiered drug prices. Nature, 2014, May-22, Volume: 509, Issue:7501 Topics: Developing Countries; Drug Costs; Drug Industry; Health Services Accessibility; Humans; Poverty; Sofosbuvir; Switzerland; Uridine Monophosphate	2014
My treatment approach to chronic hepatitis C virus. Mayo Clinic proceedings, 2014, Volume: 89, Issue:7 Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Practice Guidelines as Topic; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2014
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Antiviral Agents; Biological Transport; Carbamates; Gene Expression; HEK293 Cells; Hepacivirus; Heterocyclic Compounds, 3-Ring; Host-Pathogen Interactions; Humans; Imidazoles; Isoquinolines; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Plasmids; Pyrrolidines; Recombinant Proteins; Simeprevir; Sofosbuvir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Transfection; Uridine Monophosphate; Valine	2014
Hepatitis C: Treatment triumphs. Nature, 2014, Jun-05, Volume: 510, Issue:7503 Topics: Administration, Oral; Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
An Italian perspective: studying the cost-effectiveness of sofosbuvir before completion of national price negotiations. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:7 Topics: Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Humans; Italy; National Health Programs; Negotiating; Sofosbuvir; Uridine Monophosphate	2014
New drugs 2014, part 2. Nursing, 2014, Volume: 44, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Drug Approval; Drug Therapy; Fibrinolysin; Heterocyclic Compounds, 3-Ring; Humans; Oxazines; Peptide Fragments; Peptides; Piperazines; Pyridones; Simeprevir; Sofosbuvir; Somatostatin; Sulfonamides; Uridine Monophosphate	2014
Sovaldi makes blockbuster history, ignites drug pricing unrest. Nature biotechnology, 2014, Volume: 32, Issue:6 Topics: Drug Industry; Health Care Costs; Hepatitis C; Income; Sofosbuvir; United States; Uridine Monophosphate	2014
WHO issues guidelines on HCV amid drug cost controversy. JAMA, 2014, Jun-11, Volume: 311, Issue:22 Topics: Antiviral Agents; Drug Costs; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Practice Guidelines as Topic; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; World Health Organization	2014
Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. Journal of clinical pharmacology, 2014, Volume: 54, Issue:11 Topics: Adult; Antiviral Agents; Area Under Curve; Benzimidazoles; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Fluorenes; Half-Life; Hepacivirus; Humans; Norgestrel; Sofosbuvir; Uridine Monophosphate	2014
[Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ]. MMW Fortschritte der Medizin, 2014, Feb-20, Volume: 156, Issue:3 Topics: Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:2 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Elimination on the agenda for hepatitis C. The Lancet. Infectious diseases, 2014, Volume: 14, Issue:6 Topics: Antiviral Agents; Disease Eradication; Global Health; Hepatitis C; Humans; Injections; Interferons; Ribavirin; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate	2014
Sofosbuvir for the treatment of hepatitis C virus infection. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015, Feb-17, Volume: 187, Issue:3 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate	2015
Medicine. Hepatitis C can be cured globally, but at what cost? Science (New York, N.Y.), 2014, Jul-11, Volume: 345, Issue:6193 Topics: Antiviral Agents; Developing Countries; Drug Costs; Drugs, Generic; Global Health; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Payers consider waiting out budget-busting hepatitis C drug. Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:5 Topics: Antiviral Agents; Hepatitis C; Humans; Managed Care Programs; Medicaid; Politics; Product Surveillance, Postmarketing; Sofosbuvir; United States; Uridine Monophosphate	2014
[Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection]. MMW Fortschritte der Medizin, 2014, Jun-12, Volume: 156 Suppl 1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferons; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Secondary Prevention; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Insurers brace for high-cost Sovaldi. Modern healthcare, 2014, May-05, Volume: 44, Issue:18 Topics: Drug Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Medicaid; Sofosbuvir; United States; Uridine Monophosphate	2014
Why Sovaldi shouldn't cost $84,000. Modern healthcare, 2014, May-05, Volume: 44, Issue:18 Topics: Drug Costs; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; Uridine Monophosphate	2014
New expensive treatments for hepatitis C infection. JAMA, 2014, Aug-13, Volume: 312, Issue:6 Topics: Antiviral Agents; Drug Costs; Hepatitis C, Chronic; Humans; Nucleic Acid Synthesis Inhibitors; Sofosbuvir; Uridine Monophosphate	2014
Letter: calcineurin inhibitor level reduction during treatment with sofosbuvir in liver transplanted patients. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:4 Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins	2014
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:6 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2 Topics: Adult; Aged; Antiviral Agents; Female; Genome, Viral; Genotyping Techniques; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Phylogeny; Recombination, Genetic; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2015
US health insurers say Gilead hepatitis C drug too costly. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Jul-15, Volume: 59, Issue:2 Topics: Antiviral Agents; Health Care Costs; Hepatitis C; Humans; Insurance Carriers; Sofosbuvir; United States; Uridine Monophosphate	2014
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:1 Topics: Amino Acid Substitution; Clinical Trials, Phase III as Topic; Computational Biology; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Sequence Analysis, RNA; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate; Viral Nonstructural Proteins	2015
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transplant international : official journal of the European Society for Organ Transplantation, 2015, Volume: 28, Issue:2 Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective. Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists	2015
Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut, 2015, Volume: 64, Issue:6 Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indoles; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins	2015
The solid-gold wonder drug. A long, difficult and costly research effort gives doctors a new cure for hepatitis C. Scientific American, 2014, Volume: 311, Issue:3 Topics: Drug Combinations; Drug Costs; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2014
Guideline: New HCV drugs should go to sickest patients. JAMA, 2014, Sep-17, Volume: 312, Issue:11 Topics: Antiviral Agents; Drug Costs; Hepatitis C; Humans; Patient Selection; Practice Guidelines as Topic; Societies, Medical; Sofosbuvir; United States; Uridine Monophosphate	2014
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC infectious diseases, 2014, Volume: 14 Suppl 6 Topics: Antiviral Agents; Healthcare Disparities; Hepatitis C; Humans; Sofosbuvir; Substance Abuse, Intravenous; Uridine Monophosphate	2014
Mutant Ninja viruses. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:2 Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
[New hepatitis C treatments: pharmacological considerations and potential for drug interactions]. Revue medicale suisse, 2014, Sep-03, Volume: 10, Issue:440 Topics: Antiviral Agents; Carbamates; Drug Interactions; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine; Viral Nonstructural Proteins	2014
Editorial: patients' preferences and health utility assessment in those with HCV treated with sofosbuvir - stating the obvious? Alimentary pharmacology & therapeutics, 2014, Volume: 40, Issue:9 Topics: Antiviral Agents; Hepatitis C; Humans; Patient Acceptance of Health Care; Patient Preference; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2014
Sovaldi dilemma likely to get worse. Managed care (Langhorne, Pa.), 2014, Volume: 23, Issue:9 Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; United States; Uridine Monophosphate	2014
Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut, 2015, Volume: 64, Issue:8 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Health Care Costs; Hepatitis C, Chronic; Humans; Markov Chains; Middle Aged; Sofosbuvir; Spain; Uridine Monophosphate	2015
The uses and abuses of cost-effectiveness analysis. Modern healthcare, 2014, Aug-11, Volume: 44, Issue:32 Topics: Cost Savings; Cost-Benefit Analysis; Drug Costs; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Sofosbuvir; Uridine Monophosphate	2014
New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. Blood, 2014, Oct-16, Volume: 124, Issue:16 Topics: Adult; Female; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; RNA, Viral; Siblings; Sofosbuvir; Tissue Donors; Uridine Monophosphate	2014
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Annals of internal medicine, 2014, Oct-21, Volume: 161, Issue:8 Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Prisoners; Proline; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate	2014
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2015, Volume: 21, Issue:2 Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2015
Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:3 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Lipid Metabolism; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C. The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455 Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2014
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful? Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:1 Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Viral hepatitis: cure of chronic hepatitis C--required length of follow-up? Nature reviews. Gastroenterology & hepatology, 2015, Volume: 12, Issue:1 Topics: Antiviral Agents; Continuity of Patient Care; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Remission Induction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate	2015
Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection. AIDS research and human retroviruses, 2015, Volume: 31, Issue:2 Topics: Adult; Antiviral Agents; Coinfection; Cross-Sectional Studies; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Prevalence; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2015
FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology, 2014, Volume: 147, Issue:6 Topics: Antiviral Agents; Drug Approval; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate	2014
Building bridges and providing transparency to the hepatitis C virus drug approval process. Gastroenterology, 2014, Volume: 147, Issue:6 Topics: Antiviral Agents; Clinical Trials as Topic; Drug Approval; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2014
Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology, 2015, Volume: 148, Issue:1 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Global public health, 2015, Volume: 10, Issue:3 Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Hepatitis C; Humans; Incidence; Interferons; Markov Chains; Mass Screening; Models, Economic; Polymerase Chain Reaction; Prevalence; Quality of Life; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
Perspective: incision revision. Nature, 2014, Dec-04, Volume: 516, Issue:7529 Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Sofosbuvir; Uridine Monophosphate	2014
[Is more expensive always better?]. Nederlands tijdschrift voor geneeskunde, 2014, Volume: 159 Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Ribavirin; Sofosbuvir; Uridine Monophosphate	2014
No to greed. Southern medical journal, 2015, Volume: 108, Issue:1 Topics: Antiviral Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Drug Industry; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Practice Patterns, Physicians'; Public Health; Sofosbuvir; United States; Uridine Monophosphate	2015
Commentary on "no to greed". Southern medical journal, 2015, Volume: 108, Issue:1 Topics: Antiviral Agents; Costs and Cost Analysis; Drug Costs; Drug Industry; Hepatitis C, Chronic; Humans; Practice Patterns, Physicians'; Sofosbuvir; Uridine Monophosphate	2015
Shorter treatments for hepatitis C: another step forward? Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973 Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate	2015
A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. American journal of public health, 2015, Volume: 105, Issue:3 Topics: Adult; Antiviral Agents; Comorbidity; Drug Approval; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepatitis B; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insurance Coverage; Mental Disorders; Patient Protection and Affordable Care Act; Population Surveillance; Poverty; Prevalence; Risk Factors; Simeprevir; Sofosbuvir; Substance Abuse, Intravenous; Sulfonamides; United States; Uridine Monophosphate	2015
[Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis]. MMW Fortschritte der Medizin, 2014, Dec-15, Volume: 156, Issue:21-22 Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2014
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Alimentary pharmacology & therapeutics, 2015, Volume: 41, Issue:6 Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
Haemophilia-related outcome after liver transplantation and treatment with sofosbuvir/ribavirin in a HCV-HIV coinfected man with liver failure and hepatocellular carcinoma. Haemophilia : the official journal of the World Federation of Hemophilia, 2015, Volume: 21, Issue:2 Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Hemophilia A; Hepatitis C; HIV Infections; Humans; Liver Failure; Liver Transplantation; Male; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
PHOTON-2: hope for patients with HIV and HCV co-infection? Lancet (London, England), 2015, Mar-21, Volume: 385, Issue:9973 Topics: Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate	2015
Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science (New York, N.Y.), 2015, Feb-13, Volume: 347, Issue:6223 Topics: Amino Acid Sequence; Catalytic Domain; Conserved Sequence; Crystallography, X-Ray; Hepacivirus; Molecular Sequence Data; Protein Structure, Secondary; Ribonucleotides; RNA-Dependent RNA Polymerase; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins; Virus Replication	2015
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Costs and Cost Analysis; Efficiency; Fluorenes; Hepatitis C, Chronic; Humans; Models, Economic; Sofosbuvir; United States; Uridine Monophosphate	2015
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology (Baltimore, Md.), 2015, Volume: 61, Issue:6 Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate	2015
Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate	2015
No compelling reason to adopt new antivirals whenever it is reasonable to wait. Prescrire international, 2015, Volume: 24, Issue:156 Topics: Antiviral Agents; Enzyme Inhibitors; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Patient Safety; Risk Assessment; Risk Factors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2015
Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete . Prescrire international, 2015, Volume: 24, Issue:156 Topics: Antiviral Agents; Enzyme Inhibitors; Evidence-Based Medicine; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Patient Safety; Risk Assessment; Risk Factors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2015
[A new era in therapy of chronic hepatitis C]. MMW Fortschritte der Medizin, 2015, Feb-05, Volume: 157, Issue:2 Topics: Antiviral Agents; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Randomized Controlled Trials as Topic; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2015
[New combination therapy increases chances of recovery]. MMW Fortschritte der Medizin, 2015, Feb-19, Volume: 157, Issue:3 Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Liver Cirrhosis; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2015
[Interferon free recovery for almost all patients]. MMW Fortschritte der Medizin, 2015, Mar-05, Volume: 157, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Fluorenes; Germany; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; Uridine Monophosphate	2015
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Budgets; Cost-Benefit Analysis; Drug Costs; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Markov Chains; Patient-Specific Modeling; Quality-Adjusted Life Years; Sofosbuvir; United States; Uridine Monophosphate	2015
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Annals of internal medicine, 2015, Mar-17, Volume: 162, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Progression; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Patient-Specific Modeling; Pyrrolidines; Ribavirin; Sensitivity and Specificity; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine	2015
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Jul-15, Volume: 61, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; United States; Uridine Monophosphate; Young Adult	2015
HIV-hepatitis C co-infection. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:4 Topics: Antiviral Agents; Carbamates; Coinfection; Hepatitis C; HIV Infections; Humans; Imidazoles; Pyrrolidines; Randomized Controlled Trials as Topic; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine	2015
Assessing a broader user base for new HCV drug. The Lancet. Infectious diseases, 2015, Volume: 15, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase IV as Topic; Drug Utilization; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Annals of internal medicine, 2015, May-05, Volume: 162, Issue:9 Topics: Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Markov Chains; Monte Carlo Method; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate	2015
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:2 Topics: Anti-HIV Agents; Carbamates; Drug Combinations; Gastroenterology; Germany; Hepatitis C; Imidazoles; Internal Medicine; Pyrrolidines; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Valine	2015
Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood, 2015, Apr-09, Volume: 125, Issue:15 Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Ribavirin; Sofosbuvir; Uridine Monophosphate	2015
King of the pills. Science (New York, N.Y.), 2015, May-08, Volume: 348, Issue:6235 Topics: Anti-HIV Agents; Chemistry, Organic; Drug Discovery; Hepatitis C; History, 20th Century; History, 21st Century; Sofosbuvir; Uridine Monophosphate	2015
Dare to refuse the exorbitant price of Sovaldi! Prescrire international, 2014, Volume: 23, Issue:154 Topics: Antiviral Agents; Drug Costs; Drug Industry; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate	2014
Hepatitis C in Arkansas: updates on epidemiology, testing and treatment. The Journal of the Arkansas Medical Society, 2015, Volume: 111, Issue:12 Topics: Adolescent; Adult; Aged; Antiviral Agents; Arkansas; Cross-Sectional Studies; Drug Costs; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Ribavirin; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult	2015
Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals. The American journal of psychiatry, 2015, Volume: 172, Issue:6 Topics: Antidepressive Agents; Antiviral Agents; Citalopram; Comorbidity; Cooperative Behavior; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Forecasting; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interdisciplinary Communication; Interferon alpha-2; Interferon-alpha; Male; Mianserin; Middle Aged; Mirtazapine; Physician's Role; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2015
Campaigners challenge patent applications for hepatitis C drug in five countries. BMJ (Clinical research ed.), 2015, Jun-01, Volume: 350 Topics: Antiviral Agents; Argentina; Brazil; China; Drug Costs; Drugs, Generic; Hepatitis C; Humans; Legislation, Drug; Patents as Topic; Russia; Sofosbuvir; Ukraine; Uridine Monophosphate	2015
Thousands of patients in England to get new hepatitis C drugs. BMJ (Clinical research ed.), 2015, Jun-12, Volume: 350 Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine	2015
China rejects patent on hepatitis C drug sofosbuvir. BMJ (Clinical research ed.), 2015, Jun-23, Volume: 350 Topics: Antiviral Agents; China; Cost Control; Drug Costs; Hepatitis C; Humans; Product Surveillance, Postmarketing; Sofosbuvir; Uridine Monophosphate	2015
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. Annals of internal medicine, 2015, Aug-04, Volume: 163, Issue:3 Topics: Antiviral Agents; Drug Costs; Eligibility Determination; Health Policy; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; United States; Uridine Monophosphate	2015
Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs. Annals of internal medicine, 2015, Aug-04, Volume: 163, Issue:3 Topics: Antiviral Agents; Budgets; Drug Costs; Eligibility Determination; Health Policy; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Medicaid; Sofosbuvir; United States; Uridine Monophosphate	2015
Lawsuit seeks access to data from hepatitis C drug trial. BMJ (Clinical research ed.), 2015, Jun-30, Volume: 350 Topics: Access to Information; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fluorenes; Hepatitis C; Humans; Product Surveillance, Postmarketing; Research Design; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2015
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis. Digestive diseases (Basel, Switzerland), 2015, Volume: 33, Issue:4 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine	2015
[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA]. Zeitschrift fur Gastroenterologie, 2015, Volume: 53, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Evidence-Based Medicine; Fluorenes; Gastroenterology; Germany; Hepatitis C; HIV Infections; Humans; Practice Guidelines as Topic; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2015
Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. The American journal of gastroenterology, 2015, Volume: 110, Issue:8 Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Contraindications; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Hyperbilirubinemia; Intention to Treat Analysis; Interferons; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sepsis; Simeprevir; Sofosbuvir; Sulfonamides; Time Factors; Uridine Monophosphate	2015
Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC gastroenterology, 2015, Aug-05, Volume: 15 Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Polyethylene Glycols; Quality-Adjusted Life Years; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate	2015
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:7 Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Ultrasonography; Uridine Monophosphate; Valine	2015
Sofosbuvir (Sovaldi) for hepatitis C virus. The Nurse practitioner, 2015, Sep-13, Volume: 40, Issue:9 Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Approval; Hepacivirus; Hepatitis C; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2015
Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PloS one, 2015, Volume: 10, Issue:8 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Logistic Models; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Time Factors; United States; Uridine Monophosphate	2015
Early Patterns of Sofosbuvir Utilization by State Medicaid Programs. The New England journal of medicine, 2015, Sep-24, Volume: 373, Issue:13 Topics: Antiviral Agents; Drug Utilization; Health Expenditures; Hepatitis C, Chronic; Humans; Medicaid; Sofosbuvir; United States; Uridine Monophosphate	2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular disease. Antiviral therapy, 2016, Volume: 21, Issue:3 Topics: Aged; Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cross Infection; Disease Outbreaks; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Uridine Monophosphate	2016
Harvoni (ledipasvir and sofosbuvir) for hepatitis C. The Nurse practitioner, 2015, Nov-15, Volume: 40, Issue:11 Topics: Antiviral Agents; Benzimidazoles; Contraindications; Drug Interactions; Fluorenes; Hepatitis C; Humans; Nurse Practitioners; Patient Education as Topic; Practice Guidelines as Topic; Sofosbuvir; Uridine Monophosphate	2015
Bradyarrhythmias Associated with Sofosbuvir Treatment. The New England journal of medicine, 2015, 11-05, Volume: 373, Issue:19 Topics: Aged; Amiodarone; Antiviral Agents; Bradycardia; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate	2015
Hepatitis C drug maker puts profit ahead of patients, US Senate report charges. BMJ (Clinical research ed.), 2015, Dec-03, Volume: 351 Topics: Advisory Committees; Benzimidazoles; Conflict of Interest; Drug Costs; Drug Industry; Ethics, Pharmacy; Federal Government; Fees, Pharmaceutical; Fluorenes; Hepatitis C, Chronic; Humans; Research Report; Sofosbuvir; United States; Uridine Monophosphate	2015
Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. PharmacoEconomics, 2016, Volume: 34, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Markov Chains; Models, Statistical; Polyethylene Glycols; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Sofosbuvir; South Africa; Uridine Monophosphate	2016
Reply to "Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy". Journal of hepatology, 2016, Volume: 64, Issue:3 Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate	2016
Liver failure in human immunodeficiency virus - Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy. Journal of hepatology, 2016, Volume: 64, Issue:3 Topics: Antiviral Agents; Coinfection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Liver Failure; Sofosbuvir; Uridine Monophosphate	2016
Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury. The American journal of gastroenterology, 2016, Volume: 111, Issue:1 Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Humans; Middle Aged; Sofosbuvir; Uridine Monophosphate	2016
Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. Journal of hepatology, 2016, Volume: 64, Issue:4 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate	2016
Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5. The Lancet. Infectious diseases, 2016, Volume: 16, Issue:4 Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Uridine Monophosphate	2016
New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir. Journal of cutaneous pathology, 2016, Volume: 43, Issue:4 Topics: Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Lichen Planus; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate	2016
Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic stem cell transplant recipient. Leukemia & lymphoma, 2016, Volume: 57, Issue:11 Topics: Anemia, Aplastic; Benzimidazoles; Female; Fluorenes; Hematopoietic Stem Cell Transplantation; Hepacivirus; Hepatitis C; Humans; Middle Aged; Myelodysplastic Syndromes; Sofosbuvir; Transplant Recipients; Treatment Outcome; Uridine Monophosphate; Virus Activation	2016
[Sofosbuvir/ledipasvir is also effective in routine general practice]. MMW Fortschritte der Medizin, 2016, Apr-21, Volume: 158 Spec No 1 Topics: Benzimidazoles; Fluorenes; General Practice; Germany; Guideline Adherence; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2016
New Indications for Harvoni. The Medical letter on drugs and therapeutics, 2016, Jan-04, Volume: 58, Issue:1485 Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Approval; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate	2016
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients. Hepatology (Baltimore, Md.), 2016, Volume: 64, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2016
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. Journal of viral hepatitis, 2016, Volume: 23, Issue:10 Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Japan; Sequence Analysis, DNA; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins	2016
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS medicine, 2016, Volume: 13, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Health Expenditures; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; Uridine Monophosphate	2016
[LDV/SOF successful in general practice test]. MMW Fortschritte der Medizin, 2016, Jun-09, Volume: 158 Suppl 1 Topics: Benzimidazoles; Cohort Studies; Fluorenes; General Practice; Germany; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate	2016
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. The American journal of managed care, 2016, Volume: 22, Issue:6 Spec No. Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Longitudinal Studies; Male; Middle Aged; Multicenter Studies as Topic; Outcome Assessment, Health Care; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate; Young Adult	2016
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology, 2016, Volume: 151, Issue:3 Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine	2016
Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia. BMJ case reports, 2016, Jun-09, Volume: 2016 Topics: Benzimidazoles; Cryoglobulinemia; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2016
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2016, Volume: 19, Issue:4 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine	2016
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antiviral therapy, 2017, Volume: 22, Issue:4 Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate	2017
Successful Treatment of Pyoderma Gangrenosum with Cryoglobulinemia and Hepatitis C. The American journal of case reports, 2016, Jun-27, Volume: 17 Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Cryoglobulinemia; Fluorenes; Hepatitis C, Chronic; Humans; Male; Prednisone; Pyoderma Gangrenosum; Sofosbuvir; Uridine Monophosphate; Viral Load	2016
Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis. PloS one, 2016, Volume: 11, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Decision Support Techniques; Disease Progression; Female; Fluorenes; Hepatitis C, Chronic; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; Uridine Monophosphate	2016
[Not Available]. MMW Fortschritte der Medizin, 2016, Volume: 158, Issue:13 Topics: AIDS-Related Opportunistic Infections; Benzimidazoles; Cross-Cultural Comparison; Cross-Sectional Studies; Developing Countries; Drug Costs; Europe; Fluorenes; Hepatitis B; Hepatitis C; HIV Infections; Humans; Medical Tourism; Sofosbuvir; United States; Uridine Monophosphate	2016
Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients. Transplantation, 2017, Volume: 101, Issue:5 Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2017
Patient leaflet for Harvoni (sofosbuvir + ledipasvir): almost no information on adverse effects. Prescrire international, 2016, Volume: 25, Issue:172 Topics: Antiviral Agents; Benzimidazoles; Drug Labeling; Fluorenes; Humans; Sofosbuvir; Uridine Monophosphate	2016
The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis. Transplantation, 2017, Volume: 101, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Models, Economic; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate	2017
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation. Transplantation, 2017, Volume: 101, Issue:5 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Time Factors; Tissue Donors; Treatment Outcome; Uridine Monophosphate	2017
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2016, Volume: 22, Issue:11 Topics: Aged; Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Uridine Monophosphate	2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology, 2016, Volume: 151, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Bilirubin; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ribavirin; Risk Factors; Serum Albumin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Failure; Uridine Monophosphate; Young Adult	2016
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience. Transplantation, 2017, Volume: 101, Issue:5 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2017
Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy. Antiviral therapy, 2017, Volume: 22, Issue:1 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load	2017
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint. Tropical medicine & international health : TM & IH, 2016, Volume: 21, Issue:12 Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Industry; Drug Therapy, Combination; Fees, Pharmaceutical; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Quality Assurance, Health Care; Quality Control; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine	2016
New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners. Health affairs (Project Hope), 2016, 10-01, Volume: 35, Issue:10 Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C; Humans; Male; North Carolina; Prisoners; Prisons; Retrospective Studies; Sofosbuvir; State Government; United States; Uridine Monophosphate	2016
Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Pharmacotherapy, 2016, Volume: 36, Issue:11 Topics: Aged; Anticoagulants; Antiviral Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; International Normalized Ratio; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans; Warfarin	2016
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study. Journal of viral hepatitis, 2017, Volume: 24, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult	2017
Resolution of Porphyria Cutanea Tarda in Patients With Hepatitis C Following Ledipasvir-Sofosbuvir Combination Therapy. JAMA dermatology, 2016, 12-01, Volume: 152, Issue:12 Topics: Benzimidazoles; Biopsy; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Porphyria Cutanea Tarda; Skin; Sofosbuvir; Uridine Monophosphate	2016
The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:5 Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Decision Making; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Markov Chains; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate	2017
Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection. The Pediatric infectious disease journal, 2016, Volume: 35, Issue:12 Topics: Antiviral Agents; Benzimidazoles; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Uridine Monophosphate	2016
Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir. Acta dermato-venereologica, 2017, 04-06, Volume: 97, Issue:4 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Combined Modality Therapy; Dermatologic Agents; Disease Progression; Fluorenes; Hepatitis C; Humans; Male; Psoriasis; Risk Factors; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Ultraviolet Therapy; Uridine Monophosphate	2017
Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation, 2017, Volume: 101, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Models, Economic; Postoperative Care; Preoperative Care; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States; Uridine Monophosphate	2017
Brief Report: The Impact of Ledipasvir/Sofosbuvir on HIV-Positive and HIV-Negative Japanese Hemophilia Patients With 1, 4, and Mixed-Genotype HCV. Journal of acquired immune deficiency syndromes (1999), 2017, 04-01, Volume: 74, Issue:4 Topics: Antiviral Agents; Asian People; Benzimidazoles; Coinfection; Fluorenes; Hemophilia A; Hemophilia B; Hepatitis C, Chronic; HIV Infections; Humans; Japan; Male; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2017, Volume: 23, Issue:4 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2017
Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens. Journal of medical virology, 2017, Volume: 89, Issue:7 Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; RNA, Viral; Salvage Therapy; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins	2017
Ledipasvir/sofosbuvir without ribavirin is effective in the treatment of recurrent hepatitis C virus infection post-liver transplant. Hepatology international, 2017, Volume: 11, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2017
Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. Journal of the Formosan Medical Association = Taiwan yi zhi, 2017, Volume: 116, Issue:5 Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Fluorenes; Heart Failure; Heart Transplantation; Hepatic Encephalopathy; Hepatitis C; Humans; Liver Function Tests; Male; Middle Aged; Myocardial Infarction; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2017
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wiener klinische Wochenschrift, 2017, Volume: 129, Issue:15-16 Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Anilides; Anti-HIV Agents; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Seropositivity; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine	2017
Anti-HCV for porphyria cutanea tarda. Dermatologic therapy, 2017, Volume: 30, Issue:3 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Porphyria Cutanea Tarda; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2017
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Journal of hepatology, 2017, Volume: 66, Issue:6 Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult	2017
Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. Journal of hepatology, 2017, Volume: 66, Issue:6 Topics: Antiviral Agents; Benzimidazoles; China; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Medical Tourism; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Therapeutic Equivalency; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Jun-15, Volume: 64, Issue:12 Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans	2017
Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. Clinical transplantation, 2017, Volume: 31, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Follow-Up Studies; Glomerular Filtration Rate; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sofosbuvir; Uridine Monophosphate	2017
Treating Medicaid patients with hepatitis C: clinical and economic impact. The American journal of managed care, 2017, Volume: 23, Issue:2 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Male; Markov Chains; Medicaid; Quality-Adjusted Life Years; Sofosbuvir; Treatment Outcome; United States; Uridine Monophosphate; Viral Load	2017
Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. Journal of viral hepatitis, 2017, Volume: 24, Issue:9 Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Cost-Benefit Analysis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2017
Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert review of gastroenterology & hepatology, 2017, Volume: 11, Issue:6 Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Ireland; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Program Evaluation; Prospective Studies; Registries; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate	2017
Considerations on bringing warehoused HCV patients into active care following interferon-free, direct-acting antiviral drug approval. Postgraduate medicine, 2017, Volume: 129, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Male; Practice Patterns, Physicians'; Sofosbuvir; Surveys and Questionnaires; United States; Uridine Monophosphate	2017
Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products. Journal of AOAC International, 2017, Jul-01, Volume: 100, Issue:4 Topics: Benzimidazoles; Drugs, Generic; Fluorenes; Sofosbuvir; Tablets; Therapeutic Equivalency; Uridine Monophosphate	2017
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemporary clinical trials, 2017, Volume: 57 Topics: Adult; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Macrocyclic Compounds; Male; Patient Participation; Patient-Centered Care; Prospective Studies; Pyrrolidines; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine	2017
New Rule Requires Some Physicians to Report on Postoperative Visits. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017, Volume: 17, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Insurance Claim Reporting; Kidney Transplantation; Postoperative Care; Practice Patterns, Physicians'; Recurrence; Sofosbuvir; United States; Uridine Monophosphate	2017
Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. International journal of antimicrobial agents, 2017, Volume: 49, Issue:6 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult	2017
Experience and Outcomes of Hepatitis C Treatment in a Cohort of Homeless and Marginally Housed Adults. JAMA internal medicine, 2017, 06-01, Volume: 177, Issue:6 Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ill-Housed Persons; Male; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Cure with ledipasvir/sofosbuvir for chronic hepatitis C virus in an individual with gastric bypass. Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:5 Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Gastric Bypass; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2017
Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:5 Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Gastrectomy; Hepatitis C, Chronic; Humans; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate	2017
Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents. Journal of health care for the poor and underserved, 2017, Volume: 28, Issue:2 Topics: Antiviral Agents; Benzimidazoles; Budgets; Drug Combinations; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Patents as Topic; Public Health; Sofosbuvir; United States; Uridine Monophosphate	2017
Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection. Gut, 2018, Volume: 67, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Lipids; Male; Middle Aged; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2018
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value in health regional issues, 2017, Volume: 12 Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine	2017
Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir. Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; Kidney Transplantation; Postoperative Complications; Randomized Controlled Trials as Topic; Sofosbuvir; Sustained Virologic Response; Time Factors; Uridine Monophosphate	2017
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients. Gut and liver, 2017, Sep-15, Volume: 11, Issue:5 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Republic of Korea; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2017
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. Journal of medical virology, 2017, Volume: 89, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Lipids; Macrocyclic Compounds; Male; Middle Aged; Mutation; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Young Adult	2017
Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2017, 10-01, Volume: 137, Issue:10 Topics: Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Counterfeit Drugs; Drugs, Chinese Herbal; Ephedrine; Fluorenes; Gas Chromatography-Mass Spectrometry; Glycyrrhizic Acid; Hepatitis C; Japan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Sofosbuvir; Tablets; Uridine Monophosphate; Vitamins	2017
Two Antiviral Drugs Approved For Adolescents With HCV. The American journal of nursing, 2017, Volume: 117, Issue:8 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infant, Newborn; Sofosbuvir; Uridine Monophosphate	2017
Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation, 2017, Volume: 101, Issue:11 Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Ribavirin; Saudi Arabia; Sofosbuvir; Sustained Virologic Response; Tablets; Time Factors; Treatment Outcome; Uridine Monophosphate; Viral Load	2017
Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C. Journal of medical economics, 2018, Volume: 21, Issue:1 Topics: Adult; Benzimidazoles; Cohort Studies; Complementary Therapies; Cost of Illness; Cost-Benefit Analysis; Early Diagnosis; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Male; Middle Aged; Models, Economic; Prospective Studies; Severity of Illness Index; Sofosbuvir; United Kingdom; Uridine Monophosphate	2018
Clearance of Hepatitis C Virus Prior to Lung Transplantation: A Case Report. Transplantation proceedings, 2017, Volume: 49, Issue:7 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Lung Transplantation; Male; Middle Aged; Preoperative Care; Sofosbuvir; Uridine Monophosphate	2017
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced. Gut and liver, 2017, Sep-15, Volume: 11, Issue:5 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine	2017
Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C. Clinical journal of gastroenterology, 2017, Volume: 10, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Liver; Male; Middle Aged; Porphyria Cutanea Tarda; Sofosbuvir; Uridine Monophosphate	2017
Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube. Journal of pharmacy practice, 2018, Volume: 31, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Drug Compounding; Endoscopy, Gastrointestinal; Fluorenes; Gastrostomy; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population. Journal of viral hepatitis, 2018, Volume: 25, Issue:2 Topics: Aged; Antiviral Agents; Benzimidazoles; Black or African American; Clinical Trials as Topic; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Male; Maryland; Middle Aged; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Veterans	2018
Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. Journal of viral hepatitis, 2018, Volume: 25, Issue:2 Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Nonstructural Proteins	2018
Administration of crushed ledipasvir-sofosbuvir tablets via gastrostomy button in a patient coinfected with HIV and hepatitis C virus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, 11-01, Volume: 74, Issue:21 Topics: Anti-HIV Agents; Benzimidazoles; Female; Fluorenes; Gastrostomy; Hepatitis C; HIV Infections; Humans; Sofosbuvir; Tablets; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult	2017
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective. Value in health regional issues, 2017, Volume: 13 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Egypt; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Models, Statistical; Pyrrolidines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Uridine Monophosphate; Valine	2017
Hepatitis C Treatment with Sofosbuvir and Ledipasvir Accompanied by Immediate Improvement in Hemoglobin A1c. Digestion, 2017, Volume: 96, Issue:4 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Glycated Hemoglobin; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2017
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Scientific reports, 2017, 10-31, Volume: 7, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Cell Line; Combined Modality Therapy; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Theoretical; Sofosbuvir; Uridine Monophosphate	2017
Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. The Journal of antimicrobial chemotherapy, 2017, 10-01, Volume: 72, Issue:10 Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Spain; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2017
Resolution of porphyria cutanea tarda in HIV and mixed HCV coinfection after direct-acting antiviral (DAA) therapy. The Journal of antimicrobial chemotherapy, 2017, 10-01, Volume: 72, Issue:10 Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Middle Aged; Porphyria Cutanea Tarda; Sofosbuvir; Uridine Monophosphate	2017
Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children. Drugs of today (Barcelona, Spain : 1998), 2017, Volume: 53, Issue:8 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate	2017
Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:3 Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2018
Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report. Journal of pharmacy practice, 2019, Volume: 32, Issue:2 Topics: Adult; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Fluorenes; Hepatitis C; Humans; Male; Sexual Dysfunction, Physiological; Sofosbuvir; Uridine Monophosphate	2019
Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2019, Volume: 154, Issue:5 Topics: Aged; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Male; Sarcoma, Kaposi; Sofosbuvir; Uridine Monophosphate	2019
Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents. Histopathology, 2018, Volume: 72, Issue:6 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Inflammation; Liver Transplantation; Male; Middle Aged; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate	2018
Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV. Internal medicine (Tokyo, Japan), 2018, Apr-15, Volume: 57, Issue:8 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Skin Diseases; Sofosbuvir; Steroids; Treatment Outcome; Uridine Monophosphate	2018
Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Prescriptions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacies; Retrospective Studies; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Young Adult	2018
Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Medicina clinica, 2018, 07-23, Volume: 151, Issue:2 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Humans; Male; Middle Aged; Sofosbuvir; Uridine Monophosphate; Viral Load	2018
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam. Antiviral therapy, 2018, Volume: 23, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load	2018
Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study. Internal medicine (Tokyo, Japan), 2018, Jun-01, Volume: 57, Issue:11 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Diabetes Complications; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Serum Albumin; Sofosbuvir; Uridine Monophosphate	2018
Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals. Annals of internal medicine, 2018, 05-01, Volume: 168, Issue:9 Topics: Aged, 80 and over; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Male; Psoriasis; Remission Induction; Sofosbuvir; Uridine Monophosphate	2018
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:6 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2018, Volume: 31, Issue:1 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Tertiary Care Centers; Uridine Monophosphate	2018
EFFECTIVE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTIONS WITH DIRECT ACTING ANTIVIRALS IN PRISONS SYSTEM. Georgian medical news, 2018, Issue:274 Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; gamma-Glutamyltransferase; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Liver Function Tests; Male; Middle Aged; Prisoners; Prisons; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:7 Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation	2018
Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents. Southern medical journal, 2018, Volume: 111, Issue:3 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Blood Safety; Female; Fluorenes; Follow-Up Studies; Heart Defects, Congenital; Hepatitis C, Chronic; Humans; Male; Middle Aged; Postoperative Complications; Prevalence; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
Treatment of HCV in the Department of Corrections in the Era of Oral Medications. Journal of correctional health care : the official journal of the National Commission on Correctional Health Care, 2018, Volume: 24, Issue:2 Topics: Administration, Oral; Adult; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prisons; Ribavirin; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2018
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:10 Topics: Abdominal Pain; Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Esophageal and Gastric Varices; Fatigue; Female; Fluorenes; Gastrointestinal Hemorrhage; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nausea; Prospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2018
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. The International journal of artificial organs, 2018, Volume: 41, Issue:7 Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine	2018
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatology international, 2018, Volume: 12, Issue:2 Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Creatinine; Drug Resistance, Viral; Fluorenes; Genotype; Glomerular Filtration Rate; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult	2018
Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2018, Volume: 22, Issue:8 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine	2018
A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6- to 12- year old children. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:12 Topics: Antiviral Agents; Benzimidazoles; Child; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Pilot Projects; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate	2018
Take a Bow, Pharma, for the Hepatitis C Drugs. Managed care (Langhorne, Pa.), 2018, Volume: 27, Issue:4 Topics: Antiviral Agents; Benzimidazoles; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate	2018
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Alimentary pharmacology & therapeutics, 2018, Volume: 47, Issue:12 Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatic Encephalopathy; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine	2018
Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. The Journal of infection, 2018, Volume: 76, Issue:6 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate	2018
Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy. Journal of pharmacy practice, 2019, Volume: 32, Issue:6 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pharmacists; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. Journal of immigrant and minority health, 2019, Volume: 21, Issue:3 Topics: Africa, Eastern; Age Factors; Aged; Antiviral Agents; Benzimidazoles; Emigrants and Immigrants; Ethnicity; Female; Fluorenes; Genotype; Hepatitis C; Humans; Male; Middle Aged; Middle East; Retrospective Studies; Severity of Illness Index; Sex Factors; Socioeconomic Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate	2019
The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PloS one, 2018, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Benzimidazoles; Cohort Studies; Drug Resistance, Multiple, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Viral Nonstructural Proteins	2018
Real-World Study on Sofosbuvir-based Therapies in Asian Americans With Chronic Hepatitis C. Journal of clinical gastroenterology, 2019, Volume: 53, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult	2019
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation. Journal of gastrointestinal and liver diseases : JGLD, 2018, Volume: 27, Issue:2 Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine	2018
Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1 Infection: A Retrospective Cohort Study in a Medicaid Population. Journal of managed care & specialty pharmacy, 2018, Volume: 24, Issue:7 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medicaid; Middle Aged; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Treatment Failure; United States; Uridine Monophosphate; Viral Load	2018
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir). Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:5 Topics: Aged; Allografts; Antiviral Agents; Benzimidazoles; Biopsy; Fluorenes; Glomerulonephritis, Membranous; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Kidney; Male; Recurrence; Sofosbuvir; Uridine Monophosphate	2018
Comparative effectiveness of 8- and 12-week ledipasvir/sofosbuvir regimens for HCV infection. Antiviral therapy, 2018, Volume: 23, Issue:7 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Black or African American; Drug Administration Schedule; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Sofosbuvir; Sustained Virologic Response; Texas; Uridine Monophosphate; Viral Load; White People	2018
Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population. Digestive diseases and sciences, 2018, Volume: 63, Issue:12 Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Compliance; Prevalence; Sofosbuvir; Uridine Monophosphate; Vulnerable Populations	2018
Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis. Hepatology (Baltimore, Md.), 2018, Volume: 68, Issue:6 Topics: Adenosine Deaminase; Agammaglobulinemia; Antiviral Agents; Benzimidazoles; Fluorenes; Genetic Therapy; Hepatitis C; Humans; Infant; Male; Severe Combined Immunodeficiency; Sofosbuvir; Uridine Monophosphate	2018
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:11 Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Registries; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load	2018
Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2018, Dec-05, Volume: 205 Topics: Benzimidazoles; Fluorenes; Green Chemistry Technology; Limit of Detection; Linear Models; Reproducibility of Results; Sofosbuvir; Spectrophotometry; Tablets; Uridine Monophosphate	2018
Hepatitis C Virus Infection in ESKD Patients. Clinical journal of the American Society of Nephrology : CJASN, 2018, 11-07, Volume: 13, Issue:11 Topics: Aged; Antiviral Agents; Benzimidazoles; Benzofurans; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Mass Screening; Quinoxalines; Sofosbuvir; Uridine Monophosphate	2018
Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study. BMC infectious diseases, 2018, 08-03, Volume: 18, Issue:1 Topics: Benzimidazoles; Coinfection; Fluorenes; Glomerular Filtration Rate; Hepatitis C, Chronic; HIV Infections; Humans; Prospective Studies; Sofosbuvir; Uridine Monophosphate	2018
[Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents]. Anales de pediatria, 2019, Volume: 90, Issue:3 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2019
Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C. Digestive diseases and sciences, 2018, Volume: 63, Issue:12 Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Female; Fluorenes; Genes, Viral; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Patient Compliance; Patient Dropouts; Patient Education as Topic; Patient Medication Knowledge; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; United States; Uridine Monophosphate	2018
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Annals of hepatology, 2018, Aug-24, Volume: 17, Issue:5 Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load	2018
Effectiveness of 8 weeks of ledipasvir/sofosbuvir for hepatitis C in HCV-HIV-coinfected patients. Antiviral therapy, 2019, Volume: 24, Issue:1 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Uridine Monophosphate	2019
Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir. Journal of pediatric gastroenterology and nutrition, 2018, Volume: 67, Issue:5 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load	2018
The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study. The Pediatric infectious disease journal, 2019, Volume: 38, Issue:1 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interleukins; Male; Polymorphism, Genetic; Product Surveillance, Postmarketing; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Viral Load	2019
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:1 Topics: Antiviral Agents; Benzimidazoles; Biomarkers; Carbamates; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Prospective Studies; Prothrombin Time; Pyrrolidines; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine	2019
Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL. Digestive diseases and sciences, 2018, Volume: 63, Issue:12 Topics: Age Factors; Aged; Antiviral Agents; Benzimidazoles; California; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load	2018
Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals. Clinics and research in hepatology and gastroenterology, 2019, Volume: 43, Issue:2 Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Kidney; Living Donors; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load	2019
Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus? Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2019, Volume: 51, Issue:2 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Bradycardia; Cardiovascular System; Child; Drug Monitoring; Egypt; Electrocardiography; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load	2019
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert review of pharmacoeconomics & outcomes research, 2019, Volume: 19, Issue:3 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Markov Chains; Pyrrolidines; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Uridine Monophosphate; Valine	2019
Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. Alimentary pharmacology & therapeutics, 2018, Volume: 48, Issue:11-12 Topics: Aged; Anti-Infective Agents; Antiviral Agents; Benzimidazoles; Cardiovascular Agents; Comorbidity; Cross-Sectional Studies; Drug Interactions; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Sofosbuvir; Taiwan; Uridine Monophosphate	2018
A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:3 Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins	2019
Gilead injects own generics into shrinking HCV drug market. Nature biotechnology, 2018, 11-09, Volume: 36, Issue:11 Topics: Antiviral Agents; Benzimidazoles; Biotechnology; Drug Costs; Drug Industry; Drugs, Generic; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United States; Uridine Monophosphate	2018
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study. BMC infectious diseases, 2018, Nov-16, Volume: 18, Issue:1 Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Protease Inhibitors; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult	2018
Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals. Revista espanola de enfermedades digestivas, 2019, Volume: 111, Issue:2 Topics: Antiviral Agents; Azathioprine; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Interferons; Middle Aged; Prednisone; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:1 Topics: Aged; Antiviral Agents; Asia; Benzimidazoles; Carbamates; Cohort Studies; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Drug pricing: still a barrier to elimination of HCV. The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:12 Topics: Antiviral Agents; Benzimidazoles; Carbamates; Disease Eradication; Drug Combinations; Drug Costs; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Sofosbuvir; United States; Uridine Monophosphate	2018
Safety of pembrolizumab while commencing treatment for hepatitis C with Harvoni (ledipasvir and sofosbuvir). Internal medicine journal, 2018, Volume: 48, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antiviral Agents; Benzimidazoles; Clinical Decision-Making; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2018
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). Journal of hepatology, 2019, Volume: 70, Issue:3 Topics: Antiviral Agents; Benzimidazoles; Drug Monitoring; Duration of Therapy; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Netherlands; Outcome Assessment, Health Care; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients. Liver international : official journal of the International Association for the Study of the Liver, 2019, Volume: 39, Issue:5 Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Valine	2019
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. The lancet. Gastroenterology & hepatology, 2019, Volume: 4, Issue:2 Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Rwanda; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Viral Load	2019
Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report. BMC infectious diseases, 2018, Dec-19, Volume: 18, Issue:1 Topics: Acute Disease; Antiviral Agents; Benzimidazoles; Early Medical Intervention; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Severity of Illness Index; Sofosbuvir; Time Factors; Uridine Monophosphate	2018
Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PloS one, 2018, Volume: 13, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Taiwan; Treatment Outcome; Uridine Monophosphate	2018
Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:8 Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Elasticity Imaging Techniques; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Liver; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2019
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:9 Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Comparative Effectiveness Research; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Taiwan; Time Factors; Treatment Outcome; Uridine Monophosphate; Valine	2019
Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015. Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Costs; Drug Therapy, Combination; Female; Fluorenes; Health Care Costs; Hepatitis C, Chronic; Humans; Insurance, Health; Interferon-alpha; Male; Medicare; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Young Adult	2019
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. Journal of viral hepatitis, 2019, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C. JAMA ophthalmology, 2019, 05-01, Volume: 137, Issue:5 Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Hepatitis C, Chronic; Humans; Male; Middle Aged; Optic Disk; Retina; Severity of Illness Index; Sofosbuvir; Time Factors; Tomography, Optical Coherence; Uridine Monophosphate; Uveitis, Posterior; Visual Acuity	2019
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. PloS one, 2019, Volume: 14, Issue:4 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Safety; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult	2019
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C. Acta medica portuguesa, 2019, Mar-29, Volume: 32, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Portugal; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Young Adult	2019
Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology (Baltimore, Md.), 2020, Volume: 71, Issue:2 Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate	2020
Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection. Clinical drug investigation, 2019, Volume: 39, Issue:9 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Interactions; Female; Fluorenes; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Risk Assessment; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2019
Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Monoinfection Associated with a High Risk of Acute Liver Failure. Internal medicine (Tokyo, Japan), 2019, Oct-15, Volume: 58, Issue:20 Topics: Acute Disease; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Liver Failure, Acute; Male; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate	2019
Trends in Renal Function Among Heart Transplant Recipients of Donor-Derived Hepatitis C Virus. ASAIO journal (American Society for Artificial Internal Organs : 1992), 2020, Volume: 66, Issue:5 Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Heart Transplantation; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Kidney Diseases; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Uridine Monophosphate	2020
Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9-12 years) and adolescents. Hepatology international, 2019, Volume: 13, Issue:6 Topics: Administration, Oral; Adolescent; Adolescent Health Services; Antiviral Agents; Benzimidazoles; Child; Child Health Services; Drug Administration Schedule; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2019
Simultaneous targeted therapy for metastatic melanoma and hepatitis C. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Melanoma; Oximes; Pyridones; Pyrimidinones; Skin Neoplasms; Sofosbuvir; Uridine Monophosphate	2020
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). European journal of gastroenterology & hepatology, 2019, Volume: 31, Issue:11 Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine	2019
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients. Journal of the Formosan Medical Association = Taiwan yi zhi, 2020, Volume: 119, Issue:3 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Failure; Treatment Outcome; Uridine Monophosphate	2020
Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment. Revista espanola de enfermedades digestivas, 2019, Volume: 111, Issue:12 Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Scleroderma, Localized; Sofosbuvir; Thigh; Uridine Monophosphate	2019
A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. Advances in therapy, 2020, Volume: 37, Issue:1 Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uridine Monophosphate	2020
Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. World journal of gastroenterology, 2019, Dec-28, Volume: 25, Issue:48 Topics: Aged; Antiviral Agents; Anxiety; Benzimidazoles; Depression; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Psychological Tests; Quality of Life; Self Report; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2019
The paediatric population: the forgotten element to eliminating hepatitis C virus. The lancet. Gastroenterology & hepatology, 2020, Volume: 5, Issue:4 Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Chronic Disease; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Infectious Disease Transmission, Vertical; Liver Diseases; Male; Prevalence; Risk Factors; Sofosbuvir; Uridine Monophosphate; Young Adult	2020
Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. The Journal of pediatrics, 2020, Volume: 219 Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate	2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PloS one, 2020, Volume: 15, Issue:2 Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Uridine Monophosphate; Viral Load	2020
Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 75, Issue:6 Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Donor Selection; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Outcome and Process Assessment, Health Care; Postoperative Complications; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Viremia	2020
Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PloS one, 2020, Volume: 15, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Thailand; Time Factors; Treatment Outcome; Uridine Monophosphate	2020
Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population. Medicine, 2020, Volume: 99, Issue:11 Topics: Antiviral Agents; Benzimidazoles; Black or African American; Coinfection; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; New Jersey; Retrospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2020
Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PloS one, 2020, Volume: 15, Issue:5 Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Vietnam; Viral Load	2020
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Alimentary pharmacology & therapeutics, 2020, Volume: 52, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult	2020
Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study. Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:3 Topics: Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Thalassemia; Treatment Outcome; Uridine Monophosphate	2022
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients. Clinics and research in hepatology and gastroenterology, 2021, Volume: 45, Issue:5 Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2021
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:8 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate	2022
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug. JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71(Suppl 8), Issue:12 Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate	2021